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Polyphagia in diabetes mellitus ascribed to elevated plasma ghrelin concentrations is associated 
with prolonged postprandial hyperglycaemia due to increased activities of intestinal carbohydrate 
hydrolyzing enzymes and glucose transporters. Postprandial hyperglycaemia is a major risk 
factor in the development of diabetic complications, and as such, should be managed to prevent 
chronic vascular complications. Previous studies in our laboratory have shown that Syzygium 
aromaticum-derived oleanolic acid (OA) and maslinic acid (MA) use various mechanisms to 
lower blood glucose concentrations in experimental diabetes. The effects of these triterpenes, 
however, on intestinal glucose handling remain unknown. Accordingly, this study was designed 
to investigate the effects of these triterpenes on intestinal glucose handling in STZ-induced 
diabetic rats.  
 
Materials and methods  
OA and MA were extracted from Syzygium aromaticum cloves using a previously validated 
protocol. Briefly, S. aromaticum-derived OA and MA were sequentially extracted with 
dichloromethane and ethyl acetate to obtain ethyl acetate solubles which contained mixtures of 
OA/ursolic acid (UA) and methyl maslinate/methyl corosolate. These solubles were purified by 
silica gel 60 column chromatography with hexane: ethyl acetate solvent systems to produce OA 





Magnetic Resonance (NMR) spectroscopy and were comparable with those previously reported 
in literature. The in vitro studies investigated the inhibitory effects of OA and MA against 
enzymes such as α-amylase, α-glucosidase and sucrase. Additionally, the effects of various 
concentrations of OA and MA (0.82 - 6.56 mmol/L) on intestinal glucose transport were 
investigated using the everted intestinal sacs protocol. The in vivo studies investigated the effects 
of OA and MA on intestinal carbohydrate handling in separate groups of non-diabetic and STZ-
diabetic male Sprague Dawley rats. These studies were subdivided into oral glucose tolerance 
(OGT) responses which were carried out over two hours following loading with various 
carbohydrates as well as sub-chronic studies that were carried out over 5-weeks where the rats 
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were kept on standard rat chow. OGT responses were monitored in separate groups of non-
diabetic and STZ-induced diabetic animals the rats treated with OA and MA (80 mg/kg, p.o.). 
The rats were loaded with monosaccharides, disaccharides and polysaccharides after an 18-hour 
fast. The sub-chronic studies investigated the effects of the triterpenes on blood glucose 
concentrations over 5-weeks in groups of non-diabetic and STZ-induced diabetic male Sprague-
Dawley rats. In those animals in which the effects of OA/MA were investigated, the rats were 
administered with OA/MA (80 mg/kg, p.o.) twice daily. Blood glucose, body weights as well as 
food and water intake were assessed every third day for the duration of the experimental period. 
At the end of the experimental period, the rats were killed and blood was collected for plasma 
insulin and ghrelin measurements. Furthermore, mid portions of the small intestine were snap 
frozen in liquid nitrogen and stored in a BioUltra freezer at -70 °C for Western blot analysis of 
glucose transporters, carbohydrate hydrolyzing enzymes and ghrelin expression. Additionally, 
the effects of OA and MA on intestinal oxidative stress were evaluated through malondealhyde 
(MDA), superoxide dismutase (SOD) and glutathione peroxidase (GPx) measurements. 
 
Results  
The in vitro studies revealed that OA and MA possess inhibitory effects on the activity of α-
amylase, α-glucosidase and sucrase comparable with those of the standard drug acarbose. In 
addition, OA and MA significantly (p<0.05) inhibited intestinal glucose transport in the everted 
intestinal sacs in a dose-independent manner. The OGT studies showed that OA and MA had no 
significant effects on blood glucose concentrations in non-diabetic rats loaded with the various 
carbohydrates by comparison with the non-diabetic control. However, the triterpene-treated STZ-
diabetic rats loaded with the various carbohydrate showed significant (p<0.05) reductions in 
blood glucose concentrations by comparison with untreated STZ-diabetic rats. OA and MA 
progressively reduced blood glucose concentration as well as food and water intake over the 5-
week study in STZ-induced diabetic rats by comparison with untreated STZ-diabetic rats. 
Treatment with OA and MA had no effects on plasma insulin concentration in STZ-induced 
diabetic rats. However, these triterpenes significantly (p<0.05) reduced plasma ghrelin 
concentrations by comparison with untreated STZ-induced diabetic rats. Furthermore, rats 
treated with OA and MA showed significant (p<0.05) decreases in ghrelin, SGLT1, GLUT2, α-
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amylase and α-glucosidase expression in the gastrointestinal tract by comparison with untreated 
STZ-diabetic rats. This was accompanied by improvements in their intestinal antioxidant status 
as there were significant (p<0.05) reductions in MDA concentrations with significant (p<0.05) 
increases in SOD and GPx by comparison with the STZ-diabetic control. Additionally, OA and 
MA-treated rats showed significant (p<0.05) increases in intestinal glycogen concentrations with 
concomitant significant (p<0.05) increases in the intestinal expression of glycogen synthase by 
comparison with untreated STZ-diabetic animals.  
 
Discussion  
The results of the present study indicate that the blood glucose lowering effects of OA and MA 
in STZ-induced diabetic rats are mediated, in part, via modulating postprandial hyperglycaemia. 
These findings suggest that this is achieved through the ghrelin-mediated reduction in food 
intake leading to decreased expression of intestinal carbohydrate hydrolyzing enzymes as well as 
intestinal glucose transporters. This was followed by significant improvements in the antioxidant 
status in the rats suggesting that these triterpenes could, by preventing chronic postprandial 
hyperglycaemia, prevent the onset of the development of diabetic complications. The results of 
this study are of considerable importance as they suggest another mechanism for the anti-diabetic 
properties of the triterpenes and further explain the role of the gastrointestinal tract in the 
management of diabetes mellitus. 
Conclusion  
The results of the present study suggest that the S. aromaticum-derived triterpenes possess anti-
diabetic properties that arise, in part, through the modulation of intestinal glucose handling.  
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control.   =p<0.05 by comparison to the STZ-induced diabetic 
control. 
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Figure 33 Comparison of the effects of OA and MA administered in STZ-
diabetic rats twice every third day for 5 weeks on small intestine 
SOD activity with untreated STZ-diabetic rats and those treated 
with the standard drugs metformin and insulin. Values are 
presented as means, and vertical bars indicate SEM of means (n 
= 6 in each group).♦=p<0.05 by comparison to the non-diabetic 





Figure 34 Comparison of the effects of OA and MA administered in STZ-
diabetic rats twice every third day for 5 weeks on small intestine 
GPx activity with untreated STZ-diabetic rats and those treated 
with the standard drugs metformin and insulin. Values are 
presented as means, and vertical bars indicate SEM of means (n 
= 6 in each group).♦=p<0.05 by comparison to the non-diabetic 




Figure 35 H & E stains illustrating the effects of OA and MA on the 
morphology of the small intestine in STZ-induced diabetic rats. 
Picture A represents an intact longitudinal layer (blue arrow), an 
intact mucous membrane (yellow arrow), goblet cells in the 
circular layer (orange arrow) and normal length villi (black 
arrow) in non-diabetic control animals. Picture B represents a 
disrupted longitudinal layer (, an intact mucous membrane, 
goblet cells in the circular layer and villi with reduced length in 
untreated STZ-diabetic control animals. Pictures C, D, E and F 
represent an intact longitudinal layer, an intact mucous 
membrane, goblet cells in the circular layer and normal length 
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1.0 Background  
Intestinal glucose absorption resulting from dietary carbohydrates increases postprandial blood 
glucose to levels which are returned to within the homeostatic levels by insulin. However, in 
diabetes mellitus where there is impaired cellular glucose transport, blood glucose levels 
continually rise resulting in postprandial hyperglycaemia which is associated with the onset of 
microvascular and macrovascular complications. Therefore, controlling postprandial glucose 
levels is a critical component in the management of diabetes mellitus. Current conventional 
diabetes therapy involves the use of intense glycaemic control via insulin as well as various 
classes of oral hypoglycaemic drugs such as α-glucosidase inhibitors. These drugs prevent 
postprandial hyperglycaemia by either retarding intestinal carbohydrate hydrolysis or inhibiting 
intestinal glucose absorption. The drugs are, however, expensive and not readily available to 
populations in developing countries. Interestingly, these drugs were first isolated from medicinal 
plant products. Metformin, a standard drug used in the management of diabetes, was isolated 
from the plant Galega officinalis. Furthermore, there are a variety of plants with α-glucosidase 
inhibitory activity. While medicinal plants have drawn increasing attention as a potential viable 
source of anti-diabetic drugs for researchers across the world, the use of medicinal plant products 
in developing countries remains unabated. Of interest in this study, are the bioactive compounds 
isolated from the plant Syzygium aromaticum, oleanolic acid (3|3-hydroxy-olea-12-en-28-oic 
acid, OA) and maslinic acid (2α, 3β-dihydroxy-olean-12-en-oic acid, MA).  
 
Previous studies conducted in our laboratory demonstrated that OA and MA reduce blood 
glucose concentrations of streptozotocin (STZ)-induced diabetic rats. The mechanism(s) by 
which these triterpenes reduce blood glucose are yet to be fully established although studies 
suggest that the effects involve many organs. Indeed, both OA and MA have been reported to 
increase glycogen synthesis as well as increase glycogenic enzyme activity in both the liver and 
skeletal muscle. Furthermore, some studies suggest that OA increases insulin secretion in 
isolated rat pancreatic β-cells. Guided by these fundamental observations and thatthe blood 
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glucose lowering effects of anti-diabetic drugs are mediated via a variety of mechanisms of 
action, we hypothesized that the hypoglycaemic effects of OA and MA may involve the 
inhibition of glucose transport or the delay of carbohydrate hydrolysis in the small intestine. 
Indeed, some plant extracts lower blood glucose in experimental animals by reducing food intake 
and interfering with the effects of ghrelin in the gastrointestinal tract. The current study was, 
therefore, designed to investigate whether the blood glucose lowering properties of OA and MA 
could arise, in part, through effects on intestinal carbohydrate hydrolysis, intestinal glucose 
absorption as well as on the gastrointestinal expression of ghrelin in STZ-induced diabetic rats.  
 
Chapter 1 describes glucose homeostasis, intestinal carbohydrate metabolism, diabetes mellitus 
as well as the conventional anti-diabetic management strategies.  This chapter also describes the 
medicinal properties of OA and MA as well as justification of the study.  
 
1.1   Introduction/Literature review 
1.1.1   Glucose homeostasis 
In healthy individuals, plasma glucose levels are maintained within a relatively narrow range 
throughout the day despite large and frequent fluctuations in the delivery and removal of glucose 
from the circulation (Gerich, 2000). The diet plays a large role in the determination of blood 
glucose levels as well as ensuring that the brain receives enough energy. The brain cannot 
produce nor store glucose and is therefore primarily dependent on plasma glucose for survival.   
A fall of blood glucose concentrations to levels between 1.2 and 3.8 mM can decrease brain 
glucose uptake and trigger the release of glucagon, catecholamines, cortisol as well as growth 
hormone (Cummings et al., 2001). These hormones increase blood glucose concentrations 
through various mechanisms. A decrease in glucose concentration also triggers the secretion of 
ghrelin which results in the suppression of insulin release to prevent further decreases in blood 
glucose concentrations (Gerich, 2000; Broglio et al., 2001). An increase in glucose 
concentration, however, triggers the secretion of insulin to facilitate cellular glucose uptake. This 
results in a decrease in plasma ghrelin concentrations as well as inhibition of the processes of 
gluconeogenesis and glycogenolysis. In pathological states such as diabetes mellitus, these 
physiological processes are exploited as therapeutic targets in reducing hyperglycaemia 
(Beckman et al., 2002).  
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1.1.2   Fasting state 
Following a 14-16h overnight fast, plasma glucose concentrations average 5 mM and are 
relatively stable (Bolli et al., 1984; Gerich, 2000). Consequently, the rates of release of glucose 
into the blood must closely approximate the rates of glucose removal. During this time, there is 
no nett storage of glucose, therefore glucose taken up by tissues is either completely oxidized to 
CO2 or released back into the circulation as lactate, alanine and glutamine for reincorporation 
into glucose via gluconeogenesis (Heydari et al., 2010). Prolonged fasting causes the release of 
glucose into the circulation and this is regulated by both hormonal and non-hormonal 
mechanisms. Many tissues contain enzymes that break down glycogen to glucose-6-phosphate 
(glycogenesis) or synthesize glucose-6-phosphate from glycerol (gluconeogenesis). However, the 
liver and kidney are the only organs that mainly contain enough glucose-6-phosphatase that 
makes significant amounts of glucose (Marshall, 1991; Juhász et al., 2007). The liver is 
responsible for approximately 80% of the glucose released into circulation in this state. Of this 
amount, 50% is attributed to glycogenesis while the rest is attributed to gluconeogenesis. The 
kidney, however, normally contains little glycogen as the majority of renal cells lack glucose-6-
phosphatase. Consequently, a significant amount of the glucose released by the kidney is the 
result of gluconeogenesis (Gerich, 2000).  
Interestingly, the small intestine has also been found to express the enzyme glucose-6-
phosphatase (Rajas et al., 1999), although the extent to which this organ can store glycogen has 
not yet been determined. Considering the role of the small intestine in glucose absorption, the 
conversion of dietary glucose to glycogen could be a mechanism that prevents postprandial 
hyperglycaemia in the diabetic state.  
 
1.1.3   Postprandial state 
Postprandial glucose concentrations are defined as the glucose levels that occur after a meal. The 
total duration for complete assimilation of a meal containing carbohydrates, proteins and fats and 
the return to normal blood glucose levels takes at least 6 hours. However, the complete 
assimilation of a pure carbohydrate meal is complete within 5 hours (Gerich, 2000; Ceriello, 
2005). Humans generally consume 3 meals a day and therefore spend the majority of the day in 
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the postprandial state. Various factors play a role in the extent and the duration of the 
postprandial state. These include exogenous factors such as the amount of physical activity 
following the meal and the composition and form of the meal. These can also include factors 
such as the rate of gastric emptying, carbohydrate hydrolysis within the intestine, the rate of 
absorption of glucose across the small intestine into the hepatic portal vein, the release of glucose 
into the circulation as well as glucose uptake by the post-hepatic tissues. Once glucose uptake 
into the cells has occurred, the glucose is stored as glycogen (Hirsch, 2005; Juhász et al., 2007) . 
Therefore, the small intestine plays a major role in the determination of postprandial glucose 
concentrations. As previously mentioned, the diet is a major component influencing blood 
glucose concentrations. Feeding patterns are regulated by a hunger/satiety cycle that is regulated 
by plasma concentrations of leptin, ghrelin and insulin. However, a study showed that STZ-
induced diabetic rats exhibit polyphagia that is associated with increases in both ghrelin gene 
expression and plasma ghrelin concentrations (Masaoka et al., 2003). This abnormality 
consequently leads to chronic hyperglycaemia and therefore accelerates the progression of 
diabetic complications. Previous studies have shown the triterpenes, OA and MA, to possess 
insulin-mimetic effects (Musabayane et al., 2010; Ngubane et al., 2011). Therefore, this study 
investigated the effects of these triterpenes on ghrelin plasma ghrelin concentrations. The 




1.1.4  Ghrelin  
Ghrelin belongs to a group of conserved humoral factors characterized by strong interspecies 
homology in the composition and proportions of their amino acid constituents (Broglio et al., 
2001; Smith et al., 2005). Human ghrelin has 82.9% similarity with the rat protein and is derived 
from a 117-amino-acid preprohormone (Gul et al., 2011). Convertase cleaves a signal sequence 
from preproghrelin, and the remaining 94-amino-acid prohormone undergoes post-translational 
acylation in a serine in position 3 of the protein through the action of n-capric acid. This reaction 
is catalyzed by the enzyme ghrelin O-acyltransferase (GOAT). Proghrelin undergoes further 
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proteolytic processing by convertasePC1/3, a member of the prohormone convertase (PC) 
family, which transforms proghrelin into a 28-amino acid peptide (Smith et al., 2005). Many 
tissues express preproghrelin mRNA, but the gastric fundus has the highest levels of expression 
(Kirsz et al., 2011). A-like cells, which are mainly present in the gastric fundus have been 
reported to be the main source of ghrelin (Ariyasu et al., 2001; Smith et al., 2005). Ghrelin is the 
only known circulating hormone that acts on peripheral and central targets to increase food 
intake and promote adiposity. Approximately 55% of circulating ghrelin is produced in the 
stomach while substantially lower amounts are detected in the small intestine (25%), large 
intestine (15%), pancreas, kidney, placenta, testis, pituitary, lung, and hypothalamus (Takaya et 
al., 2000; Ariyasu et al., 2001; Masaoka et al., 2003). Ghrelin plays a major role in appetite 
regulation as studies show that this hormone stimulates feeding (Nakazato et al., 2001; Wren et 
al., 2001). In humans, ghrelin peaks before meals, suggesting the role of ghrelin as a hunger 
signal. Studies show that the biological effects of ghrelin are mediated through the specific 
receptor GHS-R, which belongs to the family of G protein-coupled receptors (GPCRs). The 
primary transcript of the GHRS gene consists of two exons and one intron. As a result of 
alternative splicing, two isomeric forms of the receptor exist: GHS-R1a and GHS-R1b. Human 
GHSR1a consists of 366 amino acids and shares 96% identity with the rat receptor. GHS-R1b 
contains 289 amino acids with five domains and does not have any biological activity (Smith et 
al., 2005). The strongest expression of GHS-R1a is in the hypothalamic cell populations that 
regulate feeding and body weight homeostasis (Zigman et al., 2006). Ghrelin binding to the 
GHS-R1a receptor results in the activation of two calcium-signaling cascades which lead to 
various metabolic processes such as changes in appetite (Broglio et al., 2001; Egido et al., 2002). 
Circulating levels of ghrelin are regulated by both short and long-term changes in nutritional 
status. Plasma levels of this peptide increase on fasting and decrease after habitual feeding, thus 
showing a pattern reciprocal to that of insulin.  
 
Studies reveal that when ghrelin is injected subcutaneously in mice, rats and humans, there is 
inhibition of insulin release (Broglio et al., 2001; Egido et al., 2002; Reimer et al., 2003; Dezaki 
et al., 2004). Low plasma ghrelin levels are associated with elevated fasting insulin levels and 
insulin resistance in humans (Poykko et al., 2003). These findings suggest both physiological 
and pathophysiological roles for ghrelin in the regulation of insulin release. Furthermore, the 
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findings raised the possibility that endogenous ghrelin has a role in physiological insulin 
secretion, and that ghrelin antagonists could improve pancreatic β-cell function (Tong et al., 
2010). Plasma ghrelin concentrations were decreased in the healthy offspring of type 2 diabetes 
subjects and the compensatory hyperinsulinaemia due to insulin resistance was associated with 
significantly reduced ghrelin concentrations (Østergård et al., 2003). A study has shown that 
fasting plasma concentrations of total ghrelin to be lower in type 2 diabetic subjects compared 
other diabetic patients (Poykko et al., 2003). These findings suggest that low blood ghrelin levels 
affect the growth hormone/insulin like growth factor-1-axis which in turn might increase insulin 
resistance and lead eventually to the development of type 2 diabetes mellitus (Barazzoni et al., 
2007). Enhanced plasma ghrelin levels have also been observed in rats with streptozotocin-
induced diabetes and are associated with diabetic polyphagia (Ariyasu et al., 2001). This increase 
in food consumption causes the body to spend more time in the postprandial state and in diabetes 
mellitus this could lead chronic hyperglycaemia. Consequently, this contributes to the 
development of diabetic complications which are discussed at a later stage. Medicinal plant 
extracts such as those from Aloe vera, Ocimum sanctum, Azadirachta indica, Solanium variabile, 
Utleria salicifolia, Asparagus racemosus and Araucaria araucana have all been reported to 
significantly reduce food intake through the reduction of plasma ghrelin levels (Bast et al., 2002; 
Fong, 2002; Dzubak et al., 2006 ; Gao et al., 2009). Syzygium aromaticum-derived OA and MA 
have been previously shown to possess insulin-mimetic properties as they reduce blood glucose 
concentrations in STZ-induced diabetic rats in sub-chronic studies through a variety of 
mechanisms. In this study, we speculated that these triterpenes reduce blood glucose levels, in 
part, through the reduction of food intake and intestinal ghrelin secretion.  The following section 









1.2   The small intestine  
The small intestine forms an integral part of the gastrointestinal tract. The primary function of 
this organ is the absorption of nutrients and minerals obtained in the diet. The small intestine is 
made up of three structural parts: the duodenum, jejunum and ileum. The length of the small 
intestine in an adult human male varies from 4.6 m to 9.8 m with glucose absorption occurring 
throughout the tract. Various studies have shown, however, that the absorption of carbohydrates 
across the small intestine is not uniform (Drozdowski and Thompson, 2006). The upper 
duodenum has been found to mostly absorb free glucose sub-units directly from the stomach 
while the lower duodenum together with the jejunum has been found to absorb the majority of 
the ingested glucose (Ferraris, 2001; Drozdowski and Thompson, 2006). This has been found to 
be due to the presence of the carbohydrate hydrolyzing enzymes that break down the 
carbohydrates into glucose sub-units thus allowing for maximal absorption. By the time the food 
reaches the upper part of the ileum, approximately 95% of glucose has been absorbed leaving the 
ileum to do the remainder of the absorption.  
Large proteins are hydrolyzed into small peptides and amino acids by pancreatic enzymes such 
as trypsin and chymotrypsin while the intestinal brush-border enzyme carboxypeptidase cleaves 
one enzyme at a time prior to absorption. Lipids are broken down into fatty acids and glycerol by 
the enzyme pancreatic lipase. Studies have shown, however, that this enzyme is water soluble 
while the fatty triglycerides are hydrophobic and tend to orient towards each other and away 
from the watery environment of the small intestine. The bile salts have been identified to be 
largely responsible for the emulsification of these fats to allow the pancreatic lipase to break 
down the triglycerides into free fatty acids and monoglycerides and thus allowing them to enter 








1.2.1   Intestinal carbohydrate metabolism  
The breakdown of starch begins in the mouth under the action of salivary amylase. Once 
swallowed, the carbohydrates are propelled through the oesophagus into the stomach. The food 
from the stomach enters the duodenum of the small intestine through the pylorus mediated by the 
pyloric sphincter. Once food enters the small intestine, the secretion of the hormone 
cholecystokinin is triggered in the small intestine. The entry of food in the small intestine also 
triggers the release of the hormone secretin that allows for the entry of bicarbonate from the 
pancreas into the small intestine for the neutralization of gastric acid.  This results in the release 
of digestive enzymes from the small intestine and pancreas.  
 
1.2.2   Amylases 
Amylases are enzymes that hydrolyze starch molecules to give diverse products including 
dextrins and progressively smaller polymers (oligosaccharides) composed of glucose units 
(Gupta et al., 2003). Amylases are widely distributed in microorganisms, plants and animals. In 
animals, amylases work together with α-glucosidases to digest complex carbohydrates into 
monosaccharides that are then absorbed (see Figure 1). They are classified into three major 
groups on the basis of the mechanism of action. Endoamylases, also known as α-amylases, 
hydrolyze internal α-(1,4)-glycosidic bonds in amylase amylopectin and related polysaccharides 
such as glycogen to produce oligosaccharides of varying chain length. In animals, these exist in 
two major isoforms, namely salivary and pancreatic amylase (Smith et al., 2005).  Exoamylases, 
also known as β-amylases cleave α-1,4-glycosidic bonds in amylase, amylopectin and glycogen 
from the non-reducing end by successive removal of maltose or glucose in a stepwise manner 
(Drozdowski and Thompson, 2006). De-branching amylases, also known as γ-amylases, 
hydrolyze mainly α-1,6-glycosidic bonds in branched starches such as amylopectin and glycogen 







1.2.3  α-glucosidases 
α-glucosidases (glycosidases) are enzymes that catalyze the hydrolysis of α(1,4) glycosidic 
linkages in starch and related compounds. These enzymes are found in the intestinal brush-
border and comprise of sucrase, maltase and iso-maltase. The major function of these enzymes is 
to hydrolyze disaccharides ingested or produced by the action of α-amylases on starch to yield 
monosaccharides which are then absorbed (see Figure 1)(Ali et al., 2002 ). A deficiency in these 
enzymes may lead to hypoglycaemia while hyperactivity of these enzymes can lead to rapid 
increases in postprandial glucose concentrations. Inhibition of this enzyme prevents a 
pronounced postprandial increase in blood glucose concentration due to delayed carbohydrate 
absorption (Ajjan and Grant, 2006). 
In diabetes mellitus the expression of enzymes such α-amylase and α-glucosidase is greatly 
elevated leading to increased rates of carbohydrate hydrolysis (Floris et al., 2005). This along 
with the lack of insulin effects leads to prolonged postprandial hyperglycaemia and subsequent 
development of diabetic complications. Some anti-diabetic drugs target the expression of these 
enzymes to slow down intestinal carbohydrate hydrolysis as a management strategy. In this 
study, we investigated the effect of OA and MA on these enzymes to not only retard intestinal 










Figure 1. Sequential carbohydrate hydrolysis by intestinal carbohydrate hydrolyzing enzymes 
yielding monosaccharides that are subsequently absorbed in the small intestine  
 
1.3   Glucose transport 
Insulin is largely responsible for the maintenance of blood glucose homeostasis through the 
promotion of glucose uptake as well as glucose utilization by cells. This leads to the storage of 
glucose in the form of glycogen in the liver and skeletal muscle. Other organs such as the kidney 
and the small intestine have been postulated to have the ability to store glycogen because of the 
presence of the enzyme glucose-6-phosphatase (Aiston et al., 2003). Insulin is synthesized by the 
β-cells of the pancreas in the islets of Langerhans in the form of pro-insulin which is further 
modified to insulin. This hormone has also been found to also stimulate protein and lipid 
anabolism as a deficiency of insulin results in weight loss through severe muscle wasting and 
lipid breakdown. This is largely attributed to the activation of hormone sensitive lipase and 
inhibition of lipoprotein lipase (Shen et al., 2007). The secretion of insulin is stimulated by 
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elevated blood glucose and fatty acid concentrations. As the concentration of glucose increases 
in the blood stream, more glucose enters the β cell through the GLUT2 transporter. This glucose 
is phosphorylated by glucokinase and subsequent reactions leading to the formation of ATP. The 
ATP: ADP ratio rises due to the oxidative and glycolytic metabolism of glucose causing ATP to 
bind and inactivate the ATP-dependent K
+
 channel. Inactivation of this channel leads to 
depolarization and an influx of Ca
2+
 leading to insulin secretion (Scheepers et al., 2004). Low 
levels of blood glucose or starvation inhibit secretion of insulin.  
Insulin receptors are present in most tissues which rely on insulin for glucose uptake. Insulin 
receptors have two components, alpha (α) components, which are found in the cell membrane 
surface and  β components which are within the cell (Saltiel and Pessin, 2002). Insulin binds to 
α- components and simultaneously activates β components. The activation of β components 
causes phosphorylation of tyrosine kinase. Tyrosine kinase activation causes phosphorylation of 
phosphoinositol 3 kinase (PI3K) which causes insertion of GLUT4 across the membrane of 
tissues such as skeletal muscle (Annandale et al., 2004). GLUT4 transporters then transport 
glucose into the cell.  Cells using this transport system are said to be insulin dependent 
(Annandale et al., 2004). After insulin binding has been terminated, insulin is released and 
circulates in the blood. Finally insulin is cleared mainly due to degradation by the liver. In 
addition to insulin dependent transporters, there are also various glucose transporters which are 
insulin independent such as sodium glucose transporters (SGLTs) as well as GLUT1 and GLUT2 
(Tahrani et al., 2013). The small intestine and kidneys use SGLTs which are sodium-mediated.  
The transport of glucose in the small intestine is determined by the amount of sodium in the 
intestinal lumen. A high concentration of sodium on the mucosal surface of cells facilitates the 
movement of glucose into the epithelial cells.  A low concentration inhibits glucose influx into 
the cells. This is because glucose and sodium share a sodium dependent glucose transporter 
(SGLT)(Furtado et al., 2002). The two isoforms of this type of transporter, SGLT1 and SGLT2, 
resemble the glucose transporters responsible for facilitated diffusion in that they contain 12 
transmembrane-spanning domains and have their carboxyl and amino terminals on the 
cytoplasmic side of the membrane (Liu et al., 2012; Tahrani et al., 2013). There is however, no 
homology with the GLUT series of transporters. These SGLT transporters are also responsible 
for glucose transport out of the renal tubules. 
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1.3.1   Mode of action of SGLT 
SGLT1 expression in the small intestine is responsive to the presence of carbohydrates in the gut 
lumen. Glucose and Na
+
 bind to the common carrier SGLT1 in the luminal membrane and 
glucose is carried into the cell as the Na
+
 moves down the electrical and chemical gradient. The 
Na
+
 is then pumped out of the cell into the lateral intercellular spaces. Glucose is transported by 
GLUT2 into the interstitial fluid. The energy for glucose transport is provided indirectly by the 
active transport of sodium out of the cell. This maintains the concentration gradient across the 
luminal border of the cell (Asano et al., 2004; Wright et al., 2011; Tahrani et al., 2013). 
Enterocytes lining intestinal villi express very large numbers of SGLT1 transporters in the apical 
(brush border) membrane. Transfer of glucose (or galactose), along with sodium from the lumen, 





-ATPase pump. The increasing concentration of glucose within the cytosol of the 
enterocyte enables the passive transfer of glucose out of the cell across the basolateral membrane 
via the sodium-independent facilitative transporter GLUT2. Glucose uptake via SGLT1 by 
intestinal K cells and L cells contributes to the secretion of gastric inhibitory polypeptide (GIP) 
and glucagon-like peptide 1 (GLP1), respectively and up-regulates GLUT2 production (Wright 
et al., 2011). In patients with diabetes, expression of SGLT1 and other monosaccharide 
transporters in the duodenum increases by 3-4 fold, suggesting that patients with diabetes have 
an increased capacity for glucose absorption (Asano et al., 2004; Wright et al., 2011). Therefore, 
aberrations in glucose transporter function can result in diabetes mellitus and the associated 










1.4  Diabetes mellitus  
Diabetes mellitus is a metabolic disorder of multiple aetiologies characterized by chronic 
hyperglycaemia, disturbances of carbohydrate, fat and protein metabolism resulting from defects 
in either insulin secretion, insulin action or both (Zimmet et al., 1997; WHO, 2006a). Diabetes 
mellitus can be categorized into three main types: type 1, type 2 and gestational diabetes. 
Type 1 diabetes is usually a progressive autoimmune disease, in which the pancreatic β-cells that 
secrete insulin are slowly destroyed by the body's own immune system. The exact mechanism 
that describes what first triggers this cascade of immune events is unclear, but there is evidence 
which suggests that both a genetic predisposition and environmental factors such as a viral 
infection are involved (Brownlee, 2001; Bonadonna, 2004).  
Rare genetic disorders such as Klinefelters syndrome and Huntington's chorea, as well as 
hormonal disorders in acromegaly, Cushing syndrome, phaeochromocytoma and 
hyperthyroidism have been associated with an increased risk for the development of type 1 
diabetes, but these account for less than 5% of reported cases (Almdal et al., 2004). Researchers 
have found at least 18 genetic locations, labeled IDDM1 - IDDM18 that are related to type 1 
diabetes. The IDDM1 region contains the HLA genes that encode major histocompatibility 
complex proteins (Bonadonna, 2004). The genes in this region affect the immune response. New 
advances in genetic research are identifying other genetic components of type 1 diabetes 
(American Diabetes Association, 2011). Ironically; most people who develop type 1 diabetes do 
not have a family history of the disease. The odds of inheriting the disease are only 10% if a 
first-degree relative has diabetes, and even in identical twins, one twin has only a 33% chance of 
having type 1 diabetes if the other has diabetes (Almdal et al., 2004). Children are more likely to 
inherit the disease from a father with type 1 diabetes (Beckman et al., 2002).  This then implies 
that genetic factors alone cannot fully explain the development of type 1 diabetes. Some 
researchers suggest that viral infections may trigger the disease in genetically susceptible 
individuals (WHO, 2006b; American Diabetes Association, 2011). Among the viruses that are 
under scrutiny are enteric viruses as these viruses attack the intestinal tract. The family of 
Coxsackie viruses are of particular interest in these studies (Brownlee, 2001; Beckman et al., 
2002). This is because epidemics of the Coxsackie virus, mumps and congenital rubella, have 
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been associated with incidence of type 1 diabetes. There are other conditions that damage or 
destroy the pancreas, such as pancreatitis, pancreatic surgery or the entry of certain industrial 
chemicals. Over the past 40 years, a major increase in the incidence of type 1 diabetes has been 
reported in some European and African countries (WHO, 2006b; American Diabetes 
Association, 2011).  
In type 2 diabetes (T2D), the pancreas still has the ability to secrete insulin, but the cells are 
partially or completely unable to utilize the insulin (Tiwari and Rao, 2002). This is referred to as 
insulin resistance and there are various theories as to why this occurs. One view is that type 2 
diabetes occurs due to genetic defects. These include defects in genes coding for glucokinase, the 
insulin molecule, the insulin receptor, GLUT 4 or the insulin receptor substrate IRS-1 (Bethel 
and Feinglos, 2002). Another view is that insulin resistance occurs due to obesity. This view 
postulates that as body weight increases, the ability of insulin to access insulin receptors  in fat 
tissue and muscle is greatly diminished (American Diabetes Association, 2011). This increases 
insulin resistance and is thus associated with type 2 diabetes. The pancreas tries to overcome this 
resistance by secreting more insulin which is why type 2 diabetes patients often exhibit 
hyperinsulinaemia (Marshall, 1991; Tiwari and Rao, 2002). T2D is typically diagnosed in 
adulthood, usually after age 45 years. At least 90% of adult individuals with diabetes have type 2 
diabetes (WHO, 2006a). T2D is usually controlled with diet, weight management, exercise, and 
oral medications. Some of these oral medications exert their effects by either slowing down the 
hydrolysis of carbohydrates in the small intestine or inhibiting glucose transport from the small 
intestine to the systemic circulation. The small intestine thus plays a large role in the 
management of diabetes and therefore justifies why this study investigated the effects of OA and 
MA on intestinal glucose handling.  
Gestational diabetes arises when there is insulin resistance which occurs during the sixth and 
seventh month of pregnancy. During pregnancy, increased levels of progesterone and oestrogen 
secreted in the placenta assist in transporting nutrients from the mother to the developing foetus. 
Other hormones like human placental lactogen and human placental growth hormone are 
produced by the placenta to help prevent the mother from developing hypoglycaemia. They work 
by resisting the actions of insulin. Over the course of the pregnancy, these hormones lead to 
progressive increases of blood glucose concentration. Usually, the mother's pancreas is able to 
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produce more insulin to overcome the effect of the pregnancy hormones on blood glucose levels. 
If, however, the pancreas cannot produce enough insulin to overcome the effect of the increased 
hormones during pregnancy, blood glucose levels will rise, resulting in gestational diabetes. 
The various types of diabetes mellitus discussed in the previous sections are all characterized by 
chronic hyperglycaemia. If untreated, they result in the development of diabetic complications 
which account for the majority of diabetes related deaths. The following section briefly describes 
the pathophysiology of the various diabetic complications.  
 
1.4.1  Aetiology of diabetic complications  
1.4.1.1  Polyol pathway  
The polyol pathway is activated in diabetes mellitus in non-insulin sensitive tissues such as the 
lenses, peripheral nerve and the glomerulus. In the pathway, the enzyme aldose reductase is 
involved in the catalysis of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent 
reduction of glucose to sorbitol. The sorbitol is oxidized to fructose by sorbitol dehydrogenase, 
an enzyme that uses NAD
+
 as a cofactor. Studies suggest that sorbitol causes osmotic vascular 
damage and cataracts in the eyes (Buse, 2006). The development of diabetic complications also 
involves the decrease in activity of enzymes that use NADPH/NADH as a cofactor. These 
include enzymes such as glutathione reductase, which would ultimately cause redox imbalances 
due to the depletion of glutathione levels (Brownlee, 2001; Sheetz and King, 2002; Lorenzi, 
2007). The generation of nitric oxide by the endothelium is also impaired by the decreased 
NADPH levels. There is also the additional inhibition of glyceraldehydes-3-phosphate 
dehydrogenase which leads to an increase in triose phosphate. The accumulation of this 
phosphate increases the formation of methylglyoxal which is a precursor of advanced glycation 
end products as well as diacylglycerol (DAG). This increase in DAG activates protein kinase C 
(PKC). The inhibition of aldose reductase by various synthetic drugs such as zenarestat and 
sorbinil has been effective in alleviating and preventing diabetic complications (Neves et al., 
2009). There are also anti-diabetic plants which have proven their success in this area.  For 
example the glycoside derivatives of the plant extracts of Stelechocarpus cauliflorous 
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[Annonaceae],engeletin and astilbin, have been reported to inhibit aldose reductase (Brownlee, 
2001). There are also plant-derived bioactive compounds that inhibit aldose reductase activity 
which include quercetin, silymarin, flavonoids and puerarin (Matsuda et al., 2001). OA and MA 
have been shown to be anti-hyperglycaemic bioactive compounds that reduce the amount of 
reactive oxygen species (Madlala et al., 2012; Mkhwanazi et al., 2014). This study investigated 
the effects of these triterpenes on both the amount of reactive oxygen species as well as 
antioxidants in the small intestine. 
 
1.4.1.2  Advanced glycation end products (AGEs) 
In diabetes mellitus, the levels of dicarbonyl compounds are elevated leading to the formation 
and accumulation of AGEs. The glycation reaction requires carbonyl groups obtained from 
glucose and carbonyl compounds such as glyceraldehyde. The formation and accumulation of 
AGEs from dicarbonyl compounds is accelerated in diabetes. AGEs have also been shown to 
reduce matrix protein flexibility through modification of extra-cellular matrix proteins leading to 
abnormal interactions with other matrix components and the receptors for matrix components on 
cells (Brownlee, 2001). The activation of these events leads to development of diabetic 
complications like retinopathy, nephropathy and atherosclerosis.  
 
There are several strategies that can be used to prevent the effects of AGEs accumulation. One 
strategy may be the use of antioxidants that inhibit the final Maillard step catalyzed by oxidative 
stress. In diabetic atherogenesis, blocking or genetically deleting receptors for AGE (RAGE) in 
experimental animals reverses atherosclerosis (Ihara and Virella, 2007). Synthetic amino 
guanidine and pyridoxamine, which are known AGEs formation inhibitors, have been found to 
have reno-protective effects in diabetic animals (Hartog et al., 2007). Additionally, the inhibition 
of AGEs effects can be achieved through breaking of the AGEs cross links by synthetic drugs 
such as alagebrium and also by inhibiting AGE signal transduction with drugs like cerivastatin 
(Hartog et al., 2007). Another strategy may be to involve glycaemic control and therefore 
prevent the glucose-dependent first step in the Maillard reaction. A well-documented strategy of 
glycaemic control involves the inhibition of glucose transport across the small intestine (Dyer et 




There are several medicinal plants with their associated derivatives that have been shown to 
prevent the complications in diabetes mellitus through the inhibition of the AGEs or RAGE 
formation (Brownlee, 2001). The extract of the plant Panaxquin quefolium (Linnaeus) 
[Araliaceae] has been shown to inhibit the formation of AGEs or RAGE (Beckman et al., 2002; 
Kudzuma, 2002). Additionally, bioactive  compounds such as resveratrol and curcumin which 
are derived from the plants Vitis vinifera (Linnaeus) [Vitaceae] and Curcuma longa (Linnaeus) 
[Zingiberaceae]  respectively, have also been found to inhibit the formation  of AGEs or RAGE 
(Sheetz and King, 2002; Rahbar and Figarola, 2003; Kim et al., 2007; Wirasathien et al., 2007). 
There are also other plant extracts that have been shown to reduce glucose transport across the 
small intestine (Mahomoodally et al., 2004). By using this mechanism, this significantly reduces 
the amount of glucose available for the formation of AGEs. Furthermore, the triterpenes of 
interest in this study have been found to improve kidney function in non-diabetic and STZ-
induced diabetes (Madlala et al., 2012; Mkhwanazi et al., 2014). Accordingly, this study 
investigated Syzygium aromaticum-derived OA on intestinal glucose transport.  
 
1.4.1.3   Protein kinase C (PKC) 
In diabetes mellitus, diacyl-glycerol(DAG) levels are increased both in vascular tissues, 
including those of the aorta, heart and renal glomeruli and also in non-vascular tissues such as 
liver and skeletal muscles (Brownlee, 2001).  DAG is a second messenger that plays a critical 
role in signaling and regulates many vascular functions such as endothelial activation, 
vasodilator release as well as growth factor signaling (Brownlee, 2001). There have been several 
pathways that have been shown to increase DAG levels in the diabetic state. One of these 
involves the hydrolysis of phosphatidylcholine by phospholipase C. The generation of the 
reactive oxygen species, like hydrogen peroxide in the polyol pathway also activates PKC. The 
activation of PKC is associated with changes in enzymatic activity, extra cellular matrix 
expansion, vascular permeability, angiogenesis, cell growth, basement membrane thickening and 
blood flow (Sheetz and King, 2002). 
 
In early diabetes, the activation of PKC has been implicated in the impairment of retinal and 
renal blood flow possibly by increasing endothelin-1 levels. The effects of PKC activation on 
nitric oxide remain unclear though there is evidence of reduced production of nitric oxide. 
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Studies show that the activation of PKC directly increases the permeability of macromolecules 
across endothelial or epithelial barriers by phosphorylating cytoskeletal proteins or indirectly by 
regulating expression of various growth factors such as vascular endothelial growth factor 
(VEGF) (Keenan et al., 2007). The majority of the diabetic manifestations due to PKC activation 
are reversed with the use of PKC inhibitors. One of these inhibitors is ruboxistaurin. This is a 
PKC-β inhibitor that has been shown to reverse haemodynamic changes in retinopathy, 
nephropathy and neuropathy (Sheetz and King, 2002; Evcimen and King, 2007). A variety of 
hydrolysable tannins purified from the plant Phyllanthus amarus have been found to inhibit 
PKC-β. However, if blood glucose levels in the diabetic state are kept within the homeostatic 
range via the inhibition of glucose uptake in the small intestine, the PKC would be inhibited 
resulting in an alleviation of diabetic complications. 
 
1.4.1.4  The hexosamine pathway  
The hexosamine biosynthesis pathway (HBP) involves conversion of fructose-6-phosphate to 
glucosamine-6-phosphate by the enzyme glutamine: fructose-6-phosphate amidotransferase 
(GFAT). The major end-product of this pathway is uridinediphosphate-acetylglucosamine (UDP-
GlcNAc). This compound along with the other amino-carbohydrates generated by hexosamine 
biosynthetic pathway (HBP) provides essential building blocks for glycosyl side chains, of 
proteins and lipids (Buse, 2006). Shunting of excess intracellular glucose into the HBP may 
account for several manifestations of diabetic renal and vascular complications (Buse, 2006). 
Therefore, there are increased amounts of fructose-6-phosphate under hyperglycaemic conditions 
diverted from glycolysis that provide substrates for reactions which require UDP-vV-
acetylglucosamine such as those of proteoglycan synthesis and the formation of O-linked 
glycoproteins (Brownlee, 2001). The altered protein function due to O-linked GlcNAcylation 
results in diminished expression of sarcoplasmic reticulum Ca
2+
 ATPase in cardiomyocytes and 
induction of TGF-P and plasminogen activator inhibitor-1 in mesangial cells, vascular smooth 
muscle cells and aortic endothelial cells (Buse, 2006). Activation of the HBP is associated with 
reduced insulin mediated translocation of GLUT-4 transporters (Furtado et al., 2002; Li et al., 
2007). Some of the effects of the HBP in diabetes include inhibition of endothelium nitric oxide 
synthase (eNOS) through hyperglycaemia-induced O-acetyl-glucosaminylation. In essence the 
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excess intracellular glucose leads to the diabetic manifestations associated with HBP (Brownlee, 
2001).  
 
There are various interventions that have been tried to alleviate the diabetic complications. These 
involve the use of hypoglycaemic drugs to inhibit the polyol and hexosamine pathways. 
Medicinal plant extracts from plants such as Phyllanthus amarus, Momordica charantia, 
Ocimum sanctum and Pterocarpus marsupium have also been investigated (Katz et al., 2007). 
The primary target in the management of diabetes mellitus is the removal of excess glucose in 
the bloodstream, which in this case is associated with complications of HBP. The control of 
glucose that enters the bloodstream is, therefore, a crucial factor and thus many conventional 
drugs such as acarbose and miglitol inhibit the absorption of glucose in the small intestine. In a 
recent study, Musabayane and colleagues showed that orally administered herbal extracts 
decrease both food consumption and blood glucose concentrations in normal and STZ-induced 
diabetic rats (Musabayane et al., 2006). Since OA and MA, which are plant derived 
triterpenoids, have been found to be anti-hyperglycaemic this study seeks to investigate the 
effects of both OA and MA on carbohydrate breakdown and absorption in the small intestine. 
 
1.5  Macrovascular complications of diabetes 
The central pathological mechanism in macrovascular disease is the process of atherosclerosis, 
which leads to narrowing of arterial walls throughout the body.  
 
1.5.1  Atherosclerosis  
Atherosclerosis is thought to result from chronic inflammation and injury of arterial walls of 
peripheral or coronary vascular vessels (Ajjan and Grant, 2006). Diabetes increases the risk of 
cardiovascular disease (CVD). CVD is the primary cause of death in people with either type 1 or 
type 2 diabetes (Laing et al., 2003; Paterson et al., 2007). Recent studies have shown that the risk 
of myocardial infarction (MI) in diabetes is equivalent to the risk in non-diabetic patients with a 
history of previous MI (Duckworth, 2001; Ajjan and Grant, 2006). Type 2 diabetes typically 
occurs in the setting of the metabolic syndrome which also includes abdominal obesity, 
hypertension and hyperlipidaemia. These other factors can also promote CVD. Even in this 
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setting of multiple risk factors, type 2 diabetes acts as an independent risk factor for the 
development of ischaemic disease, stroke, and death (Almdal et al., 2004). Among people with 
type 2 diabetes, women may be at higher risk for coronary heart disease than men. The presence 
of microvascular disease is also a predictor of coronary heart events (Avogaro et al., 2000). The 
increased risk of CVD has led to more aggressive treatment of these conditions to achieve 
primary or secondary prevention of coronary heart disease before it occurs. Studies in type 1 
diabetes have shown that intensive diabetes control is associated with a lower resting heart rate 
and that patients with higher degrees of hyperglycemia tend to have a higher heart rate, which is 
associated with higher risk of CVD (Paterson et al., 2007). Since hyperglycaemia is the generally 
the focal point of these complications, treatment and management of these complications involve 
glycaemic control which can be brought about in many ways, including the inhibition of glucose 
in the small intestine.   
 
1.5.2  Microvascular complications of diabetes 
1.5.2.1  Diabetic retinopathy  
Diabetic retinopathy is the most common microvascular complication of diabetes (Lindholm et 
al., 2002). The risk of developing diabetic complications of diabetes depends on both the 
duration and the severity of hyperglycaemia. Aldose reductase is the initial enzyme in the 
intracellular polyol pathway that participates in the development of diabetes complications. This 
pathway involves the conversion of glucose to sorbitol. High glucose levels increase the flux of 
glucose molecules through the polyol pathway, which causes sorbitol accumulation in cells. 
Cells are also thought to be injured by glycoproteins. High glucose concentrations can promote 
the non-enzymatic formation of AGEs. In animal models, these substances have also been 
associated with formation of microaneurysms and pericyte loss. Evaluations of AGE inhibitors 
are underway (Lindholm et al., 2002). Oxidative stress may also play an important role in 
cellular injury from hyperglycemia. High glucose levels can stimulate free radical production 
and reactive oxygen species formation. Animal studies have suggested that treatment with 
antioxidants, such as vitamin E, may attenuate some vascular dysfunction associated with 
diabetes, but treatment with antioxidants has not yet been shown to alter the development or 
progression of retinopathy or other microvascular complications of diabetes (Gabbay, 2004). 
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This study was designed to investigate the antioxidant effects of OA and MA in the small 
intestine.  
1.5.2.2  Diabetic nephropathy  
Diabetic nephropathy is the leading cause of renal failure worldwide. The pathological changes 
in the kidney that occur in diabetic nephropathy include increased glomerular basement 
membrane thickness, microaneurysm formation and mesangial nodule formation (Kimmelsteil-
Wilson bodies). The underlying mechanism of injury may also involve some or all of the same 
mechanisms as diabetic retinopathy. As with other complications of diabetes, prevention of the 
onset of diabetic nephropathy is part of the initial treatments. Like other microvascular 
complications of diabetes, there are strong associations between glucose control (as measured by 
haemoglobinA1c [A1C]) and the risk of developing diabetic nephropathy. Patients should be 
treated to generate the lowest safe glucose level that can be obtained to prevent or control 
diabetic nephropathy (Watkins, 2003). Treatment with angiotensin-converting enzyme (ACE) 
inhibitors has not been shown to prevent the development of microalbuminuria in patients with 
type 1 diabetes, but has been shown to decrease the risk of developing nephropathy and 
cardiovascular events in patients with type 2 diabetes (Watkins, 2003; Gross et al., 2005). There 
are several literature reports that implicate the use of plant extracts in the treatment and 
prevention of diabetic nephropathy. For example, garlic (Allium sativum) and ginger (Zingiber 
officinale) ameriolate structural nephropathy progression in streptozotocin-induced diabetic rats 
through attenuation of the SGLT1 transporters (Ali et al., 2002 ). Interestingly, these transporters 
are also found in the small intestine and play a major role in facilitating intestinal glucose 
absorption. Therefore, this study sought to investigate the effects of OA and MA, on intestinal 
glucose handling. 
 
1.5.3.3  Diabetic neuropathy 
 
The precise nature of the inflammation caused by hyperglycaemia to the peripheral nerves is not 
known, but the likelihood is that this is related to mechanisms such as polyol product 
accumulation, injury from AGEs, and oxidative stress. Peripheral neuropathy in diabetes may 
22 
 
manifest in several different forms, including sensory, focal/multifocal, and autonomic 
neuropathies. More than 80% of amputations occur after foot ulceration or injury which can 
result from diabetic neuropathy (Keenan et al., 2007). Diabetic neuropathy is, therefore, a direct 
consequence of sustained hyperglycaemia. 
 
There is no specific treatment of diabetic neuropathy, although many drugs are available to treat 
the symptoms. The primary goal of therapy is to control symptoms and prevent worsening of 
neuropathy through improved glycaemic control. Some studies have suggested that control of 
hyperglycaemia and avoidance of glycaemic excursions may improve symptoms of peripheral 
neuropathy (Gabbay, 2004). Amitriptyline, imiprimine, paroxetine, citalopram, gabapentin, 
pregablin, carbamazepine, topiramate, duloxetine, tramadol, and oxycodone have all been used 
to treat painful symptoms, but only duloxetine and pregablin possess official indications for the 
treatment of painful peripheral diabetic neuropathy (Laing et al., 2003). Treatment with some of 
these medications may be limited by side effects of the medication, and no single drug is 
universally effective. Treatment of autonomic neuropathy is targeted toward the organ system 
that is affected, but also includes optimization of glycaemic control. This is mostly achieved 
through dietary interventions in combination with drugs that alter intestinal glucose handling. 
These drugs either inhibit intestinal glucose absorption or inhibit the hydrolysis of carbohydrates 
to their monomers.  
  
1.6  Conventional management of diabetes mellitus   
Evidence from the preceding paragraphs shows that various complications can arise in diabetes 
mellitus due to prolonged postprandial hyperglycaemia. The therapies that are currently available 
do not always achieve glycaemic goals. With intensive treatment, patients may still face spikes in 
blood glucose levels after meals, weight gain and a loss of effectiveness of their treatments over 
time (Musi et al., 2002). The present therapies for T2DM mainly rely on the approaches to 
reduce hyperglycaemia by means of oral hypoglycaemic agents such as sulphonylureas, which 
increase the release of insulin from pancreatic islets; metformin, which acts to suppress 
gluconeogenesis and thus reduce hepatic glucose production; PPARγ agonists 
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(thiazolidinediones), which enhance insulin action primarily through indirect effects on lipid 
metabolism; α-glucosidase inhibitors, which interfere with gut glucose absorption and exogenous 
insulin injections, which suppress glucose production and augment glucose utilization (Kellett 
and Helliwell, 2000; Stumvoll et al., 2000; Dhindsa et al., 2002). The following sections briefly 
discuss the various classes of compounds, which include α-glucosidase inhibitors that are used in 




Figure 2: The various classes of compounds used in the management of diabetes mellitus. These 
classes use various mechanisms to maintain glucose homeostasis. 
 
1.6.1   Insulin  
The various insulin formulations are classified based on the duration of action. and there are 
three main types; short-acting, intermediate-acting and long-acting (Bethel and Feinglos, 2002; 
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Vazquez-Carrera and Silvestre, 2004). The short-acting class is designed to mimic bolus insulin 
secretion which is used in emergency situations, while intermediate or long acting insulin classes 
are designed to mimic basal glycaemic control and are more suitable for long term management 
of diabetes (Vazquez-Carrera and Silvestre, 2004). A disadvantage of subcutaneously delivered 
insulin is that this insulin is delivered in a bolus. With this method of delivery, the diabetic 
patient runs a risk of developing hyperinsulinaemia which can result in severe hypoglycaemia.  
At extremely low blood glucose levels, patients can exhibit lethargy which can lead to coma, 
convulsions and eventual death.  
 
Due to the short half-life of insulin, there is a need for multiple insulin injections daily in order to 
maintain homeostatic blood glucose levels. This results in decreased patient compliance as the 
process is not only cumbersome, but also painful as this is an invasive method. This method 
however, has been found to be efficient in managing postprandial hyperglycaemia as the 
injections are administered with every meal. Recent studies have shown the small intestine to be 
an insulin-sensitive organ as the small intestine expresses the enzyme glucose-6-phosphatase 
which is involved in both gluconeogenesis as well as glycolysis (Aiston et al., 2003). This 
suggests that the small intestine could be a site for glucose storage. Furthermore, insulin has been 
found to inhibit the intestinal absorption on glucose in vitro (Stümpel et al., 1996 ; Lidia et al., 
2010). This suggests that the hypoglycaemic effects of insulin observed in diabetes mellitus 
could arise, in part, via the effects on the small intestine.  
 
The subcutaneous administration of insulin, however, is more suitable to the management of type 
1 diabetes (Aiston et al., 2003; Hirsch, 2005). Type 2 diabetes management, however, requires a 
different approach as insulin is still present. There are various classes of compounds that are used 









1.6.2  Thiazolidinediones 
 
Thiazolidinediones (TZD’s) are orally administered hypoglycaemic agents that require the 
presence of insulin to exert their effects. They are mainly used in the management of type 2 
diabetes mellitus. These compounds are known to exert their hypoglycaemic effects by 
increasing insulin sensitivity in tissues such as skeletal muscle and adipose tissue to enhance 
insulin effects (Bailey, 2011). TZD’s are selective and potent agonists for the peroxisome 
proliferator-activated receptors (PPARγ. These receptors are found on insulin-sensitive tissues 
and not only act as lipid sensors, but also as regulators of carbohydrate and lipid metabolism. 
Activation of PPAR γ  improves insulin sensitivity resulting in increased glucose uptake in the 
skeletal muscles and reduced hepatic glucose output (Ajjan and Grant, 2006). Commercially 
available TZD’s include troglitazone, pioglitazone and rosiglitazone. The drugs have been found 
to modulate most of the risk factors associated with cardiovascular diseases (Kudzuma, 2002). In 
addition, TZD’s modify lipid profiles and prevent inflammation and atherosclerosis in vascular 
tissues as well as lower blood pressure in diabetic patients. These drugs, have not been found to 
influence intestinal glucose handling as yet, but have been associated with increased glycogen 
synthesis in the liver and skeletal muscle (Sun, 2006). 
 
1.6.3   Sulphonylureas 
 
Sulphonylureas (SU), also known as insulin secretagogues, are orally administered 
hypoglycaemic agents which exert their hypoglycaemic effects primarily by increasing the 
release of insulin from residual functioning pancreatic β cells. Drugs such as tolbutamide and 
gliclazide exert their effects by blocking the SUR1 subunit, whereas drugs like glibenclamide 
and glimepiride have high affinity for both SUR1 and SUR2. The class of drugs has additional 
effects because the SUR2 receptors are also present on the KATP channels of cardiac (SUR2A) 
and vascular smooth muscles (SUR2B) and are thus able to assist the heart adapt during 
ischaemic conditions through dilatation of coronary vessels (Ajjan and Grant, 2006). SU’s are 
used with extreme caution as their effects cannot be regulated. These drugs cause the release of 
insulin irrespective of the blood glucose concentration and this can result in severe 
hypoglycaemia (Ajjan and Grant, 2006). While studies reveal that insulin may play a role in 
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intestinal glucose handling, these drugs have not been found to exert any effects on the small 
intestine.  
 
1.6.4   Biguanides 
 
Biguanides are a class of orally administered anti-diabetic drugs that lower blood glucose by 
mainly reducing hepatic gluconeogenesis and increasing skeletal muscle glucose uptake and 
utilization (Musi et al., 2002). Most of these drugs exert their effects by activating AMP-
activated protein kinase (AMPK). This is an enzyme which plays a major role in the stimulation 
of glucose uptake in skeletal muscle (Musi et al., 2002), but also by inhibiting liver 
gluconeogenesis (Grover et al., 2002; Lidia et al., 2010). The AMPK pathway is usually 
activated in response to the depletion of cellular energy stores observed in diabetes mellitus. 
Metformin has also been reported to increase muscle hexokinase (HK) activity in STZ-induced 
diabetic rats (Dyer et al., 2002). HK plays an important role in the maintenance of glucose 
homeostasis in all cells that are metabolized by ATP to produce G-6-P (Bonadonna, 2004; 
Ndong et al., 2007). Metformin has been reported to delay the digestion of complex 
carbohydrates in the small intestine while some studies suggest that biguanides may shunt some 
glucose towards glycogen synthesis within the small intestine (Dhindsa et al., 2002; Ali et al., 
2002 ). However, there is paucity of studies that have investigated the effects of these biguanides 
on intestinal glucose handling. This study therefore investigated the effects of OA and MA on 
intestinal glucose handling as well as glycogen synthesis in the small intestine. 
 
 
1.6.5   Intestinal enzyme inhibitors  
 
Studies during the last few decades have identified a number of carbohydrate hydrolyzing 
enzymes as possible targets for diabetes management. These include enzymes such as α-






1.6.5.1  α-amylase inhibitors  
The activity of α-amylases is reported to be inhibited by metal chelators, organic acids, heavy 
inorganic metal ions, pure natural products as well as crude plant extracts (Muralikrishna and 
Nirmala, 2005). Metal chelators are strong inhibitors of amylases as they are metalloenzymes 
(Matsuda et al., 2001; Yong and Robyt, 2003). Organic acids such as citric acid and oxalic acid 







 have been known to inhibit amylases at high concentrations (Muralikrishna and 
Nirmala, 2005). Acarbose, a synthetic pseudotetrasaccharide originally isolated from actinoplane 
species of microorganisms is used in the management of diabetes mellitus. Acarbose has the 
ability to inhibit both α-amylase and α-glucosidase (Yong and Robyt, 2003). Interestingly, 
various studies have confirmed the α-amylase inhibitory activity of medicinal plant extracts. A 
majority of plant extracts that have been investigated have showed strong α-amylase inhibitory 
effects that compare with those of the standard drug acarbose. Table 1 shows a few of the plants 


















Table 1. Various medicinal plant extracts that have been reported to possess α-amylase inhibitory 
activity. They are given in order of increasing IC50 values together with their maximum 
percentage inhibition values.  
 





Phyllanthus amarus Hexane 100 0.003 (Patel et al., 
2011) 
Ocinum tenuiflorum Aqueous  76 1.6 (Bhat et al., 
2008) 
Murraya koenigii Aqueous 84 1.9 (Bhor et al., 
2004) 
Morus alba Ethanolic 76 18 (Abdul-Ghani 
and Defronzo, 
2014) 
Salvia veticilata Ethanolic 100 18 Nickavar et al., 
2008 




Ethanolic 80  51 Subramanian et 
al.,  2008 








1.6.5.2  α-glucosidase inhibitors 
 
α-glucosidase inhibitors such acarbose (precose) and miglitol (glyset) are orally administered 
anti-diabetic drugs that exert their hypoglycaemic effects by either inhibiting glucose absorption 
in the small intestine or slowing down the hydrolysis of carbohydrates (Tiwari and Rao, 
2002).These agents can also exert their effects via either inhibition of other digestive enzymes 
such as α–amylase (Kim et al., 2008). α-glucosidase inhibitors can also exert their effects via the 
inhibition of active transport of glucose across the intestinal brush border membrane or by 
decreasing gastric emptying (Mahomoodally et al., 2005). The inhibition of glucose transport 
mechanism relies heavily on the interaction with the SGLTs in the small intestine. These 
transporters aid in the transfer of glucose from the mucosa to the serosa. Although there are a 
few commercially available α-glucosidase inhibitors, various medicinal plant extracts have been 
shown to lower blood glucose concentrations through inhibition of α-glucosidase.  
 
Pharmacologically, the potency (inhibitory strength) of a medicinal enzyme inhibitor is reported 
in terms of the compounds IC50 value. This is the concentration at which the inhibitory 
compound reduces the enzyme activity by 50%. The IC50 value depends on concentrations of the 
enzyme (or target molecule), the type of inhibitor used as well as the substrate along with other 
experimental conditions. Inhibitors that require a smaller concentration to reduce the enzyme 
activity by 50% have smaller IC50 values suggesting that the lower the IC50 value, the greater the 
inhibitory potency of the compound. Studies have reported that medicinal plants extracts like 
those derived from Momordica charantia not only exert their hypoglycaemic effects by 
inhibiting α-glucosidase activity but that they also have IC50 values comparable to those of drugs 
such as acarbose and miglitol (Mahomoodally et al., 2004). Recent studies that have identified 







Table 2. Medicinal plant extracts that have been reported to have α-glucosidase inhibitory 
activity. They are given in order of increasing IC50 values together with their maximum 
percentage inhibition values.  
 














Grateloupia elliptica Ethyl acetate 64 4.8 Kim et al.,  2008 




Andrographis paniculata Ethanolic 80 17.2 (Tandon et al., 1993) 
Bergenia ciliate Methanolic 69 33.3 (Bhandari et al., 
2008) 
Euclea undulate Ethanolic 62 49.5 (Deutschlander et al., 
2009) 




1.6.5.3  Intestinal glucose transport inhibitors 
In the 1980s, Rossetti and colleagues introduced the concept of normalization of glucose 
concentrations by increasing urinary glucose excretion (Rossetti et al., 1980). The researchers 
showed that phlorizin, a naturally occurring phenolicglycoside first isolated from apple tree bark 
in 1835 increased urinary glucose and lowered blood glucose in partly pancreatectomised rats. In 
31 
 
the 1990s, phlorizin was identified as an inhibitor of the SGLT1 and SGLT2 transporters. 
However, phlorizin offered little oral bioavailability because of degradation at an O-glucoside 
linkage by intestinal glucosidases. In addition, the poor selectivity for blockade of SGLT2 
compared with SGLT1 in the intestine caused sufficient gastrointestinal side-effects to exclude 
this drug as a treatment for patients with type 2 diabetes. Although several potent selective 
SGLT2 inhibitors such as T1095, sergliflozin, and remogliflozin were developed, they are 
degraded by intestinal glucosidases at their O-glucoside linkage and have not progressed in 
clinical development. Oral SGLT inhibitors that are either approved or in advanced clinical 
development have circumvented glucosidase degradation by replacement of the O-glucoside 
linkage with a C-aryl linkage. Inhibitors of SGLT2 eliminate 60–80 g of glucose per day and 
sustain this for 2 years in clinical trials. This elimination represents inhibition of reabsorption of 
about a third of the filtered glucose load. The extent to which SGLT2 can be inhibited varies 
with the dose, binding affinity, and retention time of the inhibitor at the transporter. Exposure of 
the inhibitor to the transporter also shows the rate at which the inhibitor is filtered, secreted or 
reabsorbed by the proximal tubule. Inhibition of glucose reabsorption by SGLT2 will be partly 
off-set by the uptake of glucose by SGLT1. Because inhibition of SGLT2 and SGLT1 is not 
insulin-dependent, and is not altered by deteriorating β-cell function or insulin resistance, these 
inhibitors should in principle be operative at any stage in the natural history of diabetic states. 
However, although these inhibitors can reduce hyperglycaemia, they do not directly address the 
fundamental underlying endocrinopathies. Thus, although a sustained reduction in glucotoxicity 
improves the metabolic environment and reduces hyperglycaemia-related complications, insulin 
is always necessary to meet other physiological requirements. Many studies have reported the 
efficacy of various medicinal plant extracts in inhibiting intestinal glucose absorption 
(Mahomoodally et al., 2005; Mahomoodally et al., 2006; Gao et al., 2008). Plants extracts of 
Neurolena lobata and Luthrum salicaria have all been shown to be able to completely inhibit 
intestinal glucose absorption in vitro while the extracts of plants such as Fraxinus excelsior and 
Momordica charantia have been shown to avert hyperglycaemia in vivo through this mechanism 






1.7   Traditional plant extracts 
As mentioned previously, current conventional diabetes therapy using blood glucose-lowering 
medications such as insulin or oral hypoglycaemic agents has limitations. Alternative methods of 
lowering blood glucose are therefore needed. The World Health Organisation (WHO) estimated 
that 80 % of the population of developing countries relies on traditional medicines, mostly plant 
drugs, for their primary health care needs (Matsuda et al., 2001; Raptis and Dimitriadis, 2001). 
Scientific investigations of the plant extracts that possess hypoglycaemic effects not only assists 
in validating indigenous knowledge systems, but could also provide a more affordable alternative 
source of anti-diabetic drugs. Extracts of the plants Erythroxylum macrocarpum 
(Erythroxylaceae), Punica granatum, Rosa damascena and Vaccinium arctostaphylos have all 
been found to possess anti-diabetic properties (Grover et al., 2002). Further investigations reveal 
that these plants exhibit their anti-diabetic properties using different mechanisms such as 
reducing food intake, stimulating insulin secretion, increasing glycogen synthesis and delaying 
carbohydrate digestion. This is testament that the various plants used around the world to 
manage diabetes are a rich source of anti-diabetic drugs and possess the potential to finding the 
ideal drug to manage diabetes. For instance, the use of herbs and medicinal plant products has 
become a mainstream phenomenon over the past two decades in the United States where herbs 
and phytomedicines have become one of the fastest growing segments in retail pharmacies and 
supermarkets (Antignac et al., 2011; Delhanty and van der Lely, 2011). In Asian regions such as 
India and China, western scientists have rediscovered many of these traditional medicines as 
cheap sources of complex bioactive compounds (Ndong et al., 2007). A significant number of 
many potent drugs used today trace their origins to plants (Al-Qattan et al., 2008). For instance, 
the anti-diabetic drug metformin was isolated from the plant Galega officinalis (Linnaeus) 
[Fabaceae]. Another anti-diabetic drug that is used to delay the digestion of carbohydrates in the 
small intestine, acarbose, is derived from various plants such as Phaseolus vulgaris and Irvingia 
gabonensis (Al-Qattan et al., 2008). Currently, several kinds of plant extracts from various 
exotic, endemic and indigenous plants are sold as decoctions in several markets globally to treat 
diabetes mellitus, but very few of these have been validated scientifically for their therapeutic 
efficacy. Some of these plants extracts, while hypoglycaemic, have other negative side-effects 
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such as kidney failure, increase blood pressure and lead to inflammatory responses due to 
possessing antigenic properties (Katz et al., 2007). These extracts contain many compounds, 
some of which are toxic. Some of the compounds found in these extracts are not naturally toxic, 
but because they are given in excessively high amounts they become toxic. This has led to the 
identification and isolation of the bioactive compounds responsible for the hypoglycaemic 
effects to investigate their individual effects.  
 
Some of the work in our laboratory thus far has investigated the blood glucose lowering effects 
of crude plant extracts. These include the extracts derived from plants such as Persea americana 
(Miller) [Lauraceae], Sclerocarya birrea [(A. Rich) Hochst.] Ficus thonningii (Blume) 
[Moraceae] and Psidium guajava. More recently, the focus has been on plants of the Syzygium 
species, these include plants such as Syzygium cordatum as well as Syzygium aromaticum 
(Ngubane et al., 2011; Madlala et al., 2012; Mkhwanazi et al., 2014). Other studies also showed 
that these extracts contained pentacyclic triterpenoids (Chen et al., 2006).  
 
1.7.1  Syzygium aromaticum 
Syzygium aromaticum is a clove tree that belongs to Myrtaceae family (See Figure 3). This plant 
is an evergreen tree that grows to a height of 15 to 30 meters and is native in North Moluccas 
(Indonesia). This plant  is also grown in India, Jamaica, Brazil, and other tropical areas (Agbaje 
et al., 2009). S. aromaticum has opposite; ovate leaves which are more than 5 inches long. When 
fully grown, the flowers are red and white, bell-shaped, and grow in terminal clusters.  S. 
aromaticum also has brown, dried, unopened flower buds that are called cloves. These cloves are 
familiarly used in cooking and the fruit is a one- or two-seeded berry (Agbaje et al., 2009). The 
leaves of the plant are glabrous, with numerous oil glands on the lower surface. S. aromaticum 
contains bioactive chemical compounds which include tannins, glycosides,saponins, polyphenols 
and triterpenes. An essential oil is produced from the cloves of this plant and this oil is used to 
add aroma to food. The main constituents of the oil are eugenol (70-85%), eugenol acetate 
(15%), β-caryophyllene (5-12%). The triterpenes, ursolic acid (UA), oleanolic acid (OA) and 
maslinic acid (MA) make up the remainder of the constituents of this oil. However, the UA has 
been found, in previous studies conducted in our laboratory, to be toxic to tissues resulting in the 
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investigations being discontinued (Musabayane et al., 2007). This study, therefore seeks to 
investigate the effects of OA and MA on intestinal glucose handling.  
 
Figure 3: Syzygium aromaticum plant. Picture adapted from (Raina et al., 2001) 
 
1.8   OA 
Oleanolic acid (3|3-hydroxy-olea-12-en-28-oic acid, OA is a plant pentacyclic triterpene found 
as free acid or aglycones for triterpenoid saponins (Liu, 1995). This compound appears 
abundantly as a major constituent in many African medicinal plants (Al-Qattan et al., 2008; Liu 
et al., 2012). OA has therapeutic importance due to the triterpenes low systemic toxicity as well 
as diverse pharmacological properties (Liu, 1995; Braga et al., 2007; Patil et al., 2010). OA 
possesses anti-inflammatory and anti-oxidant properties (Teodoro et al., 2008). In our laboratory, 
this triterpene has been shown to possess hypoglycaemic, hypotensive, reno- and cardio-
protective effects in experimental animals (Musabayane et al., 2005; Mapanga et al., 2009; 
Musabayane et al., 2010). The effects of this triterpene on postprandial glucose concentrations 
however, have not yet been established. This study therefore investigated the effects of this 




1.9  MA  
The pentacyclic triterpene, maslinic acid (MA) (2a, 3b-2,3-dihydroxy-olean-12-en-28-oic acid), 
has wide-spread occurrence throughout the plant kingdom. This compound possesses a broad 
spectrum of pharmacological properties which include anti-inflammatory, anti-humoral, 
hepatoprotective, anti-oxidation, antibacterial and anti-HIV effects (Aiston et al., 2003; Dzubak 
et al., 2006 ; Juhász et al., 2007). In addition this triterpene has previously been shown to have 
hypoglycaemic effects via antagonism of hepatic glucose production (Liu, 2008; Tarling et al., 
2008). MA has been previously reported to present a new class of glycogen phosphorylase (GP) 
inhibitor (Aiston et al., 2003; Juhász et al., 2007). This bioactive compound causes 
pharmacological inhibition of this key enzyme responsible for glycogen breakdown thus 
providing a therapeutic approach for treating diseases associated with abnormalities in glycogen 
metabolism. The increase in glycogen synthesis caused by MA enhances glucose utilisation thus 
decreasing blood glucose (García-Granados et al., 2000; Reyes-Zurita et al., 2009). In addition, 
MA has been reported to possess hypoglycaemic properties in adrenaline-induced diabetic mice 
(Al-Qattan et al., 2008). Furthermore, studies have shown that this triterpene ameliorates kidney 
function through increased glomerular filtration rate and increased urinary sodium output in 
STZ-induced diabetic rats. The effects of this triterpene on postprandial glucose concentrations 
however, have not yet been established. This study therefore investigated the effects of this 
triterpene on intestinal carbohydrate hydrolyzing enzymes and intestinal glucose transport.  
 
 
1.10  Experimental techniques used to study intestinal glucose handling  
There are various methods available for studying glucose handling in the gastro-intestinal tract, 
but they all have certain limitations. The serial measurement of blood glucose concentrations 
after the oral administration of carbohydrates is an indirect method influenced by many factors 
besides intestinal absorption. These studies, however, do not account for the disappearance of 
glucose which may be influenced by such factors as bacterial decomposition in the large intestine 
(Zakeri-Milania et al., 2007). One technique that was used for measuring the rate of absorption 
of sugars in the intact animal was by giving a sugar by stomach tube and then killing the animal 
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and measuring the amount of sugar recovered from the gastro-intestinal tract (Reynell and Spray, 
1956). This method is open to the objections that variations in gastric emptying and intestinal 
transit cannot be taken into account and the site of absorption cannot be determined. Another 
method of evaluating intestinal glucose handling is the in situ jejunal perfusion technique. This 
technique is a well-established technique to investigate the intestinal absorption behavior of both 
drugs and carbohydrates in which the glucose is monitored in perfusate. This technique offers the 
advantage of being able maintain high intestinal enzyme activity, however,  organ integrity as 
well as enzyme activity may become fragile and compromised during long-term perfusions (Liu 
and Liu, 2013). Another in vitro technique used to assess intestinal function is the use of Caco-2 
cells. These cells are derived from human colorectal adenocarcinomas and form monolayer (like 
human intestinal epithelium) under conventional culture conditions. They have been widely used 
as a potent in vitro model to predict drug absorption in humans, to explore mechanisms of drug 
absorption, and to identify substrates or inhibitors of transporters (Sjoberg et al., 2013). These 
cells exhibit remarkable morphologic and biochemical similarity to the small intestinal columnar 
epithelium; they are extremely useful for mechanistic studies of drug absorption and are widely 
used by pharmaceutical companies in absorption screening assays for preclinical drug selection. 
Although Caco-2 cells system has many advantages, there also include some limitations such as 
the long (21 day) cell culturing time, heterogeneity, and non-specificity due to the expression of 
multiple transporters.   
 
 
The everted intestinal sac technique is a widely used in vitro model to evaluate the absorption of 
drugs by transporters (Wilson and Wiseman, 1954). This system offers the advantage of being 
able to monitor glucose transport across the small intestine through the quantification of glucose 
(Mahomoodally et al., 2004). Furthermore, the cells of the small intestinal tissue receive 
sufficient amounts of oxygen throughout the experimental period thus keeping them alive for the 
duration of the experiment. Additionally, this technique requires a low number of animals for 
experiments as many intestinal segments can be obtained from each animal. This technique was 
employed in this study to evaluate the effects of triterpenes on intestinal glucose absorption. This 




1.11   Justification of the study  
Postprandial hyperglycemia ascribed to hydrolysis of carbohydrates by digestive enzymes in the 
small intestine is a major risk factor for complications in diabetic patients. Small intestine α-
glucosidase and pancreatic α-amylase are the key enzymes of dietary carbohydrate digestion in 
humans. Glucose released upon carbohydrate digestion is absorbed from the intestinal lumen into 
the blood mainly via sodium-dependent glucose co-transporter (SGLT1), localized to the 
enterocyte apical or brush-border membrane (BBM), and the basolateral facilitative glucose 
transporter 2 (GLUT2). Evidence obtained from experimental diabetes indicates that the capacity 
of the small intestine to absorb glucose in diabetes increases mainly due to enhanced activity and 
abundance of SGLT1 and GLUT2. Thus, controlling postprandial glucose concentrations is 
critical during early treatment of diabetes mellitus to avert postprandial glucose excursions 
thereby reducing chronic vascular complications. Commercially available synthetic inhibitors of 
carbohydrate hydrolyzing enzymes are effective in retarding carbohydrate hydrolysis and 
glucose absorption to suppress postprandial hyperglycaemia. Furthermore, dietary interventions 
are incorporated into many diabetes management strategies so as to reduce food intake without 
compromising the nutritional status of the individual. α-glucosidase inhibitors with increased 
potency and lesser adverse effects than the existing drugs have also been isolated from medicinal 
plants. Interestingly, various medicinal plant extracts have been found to influence food intake 
through the modulation of plasma ghrelin concentrations as well as through the attenuation of 
intestinal carbohydrate hydrolyzing enzymes. We have reported that the hypoglycaemic 
properties of plant-derived oleanolic acid (OA) and maslinic acid (MA) are mediated via other 
mechanisms such as increased glycogenesis. However the effects on key carbohydrate 
hydrolyzing enzymes remain unanswered. Therefore, the present project was designed to 
evaluate the effects of Syzygium spp-derived triterpenes oleanolic acid (OA) and maslinic acid 
(MA) on intestinal glucose handling in normal and STZ-induced diabetic rats. This was done 
through the evaluation of the triterpene effects on postprandial hyperglycaemia associated with 
various carbohydrates and their hydrolyzing enzymes; intestinal glucose transport and the 
expression of the respective glucose transporters as well as evaluating the effects of the 





 MATERIALS AND METHODS 
2.0   Drugs and chemicals 
Drugs and chemicals were sourced as indicated:  
streptozotocin (STZ), Tris-HCl, dimethyl sulphoxide (DMSO), acarbose, porcine pancreatic 
amylase (PPA), α-glucosidase, sodium docedyl sulphate (SDS), glycerol, phenyl methyl sulphonyl 
fluoride (PMSF), bicinchoninic acid (BCA) reagent, nitrocellulose membrane, Trizma base (tris), 
triton X-100, ethidium bromide, ethylenediaminetetraacetic acid (EDTA), sodium bicarbonate 
(NaHCO3), sodium chloride (NaCl), potassium chloride (KCl), dipotassium phosphate (K2HPO4) 
and sodium hydroxide (NaOH)(Sigma-Aldrich, St Louis, Missouri, United States of America); 
 
acetic acid, citric acid, sodium citrate, hexane, dichloromethane (DCM), ethyl acetate (EA), 
methanol, calcium chloride, potassium hydroxide, potassium chloride, 95% ethanol (C2H5OH), di-
sodium hydrogen orthophosphate dehydrate, sodium dihydrogen orthophosphate dihydrate, 
sucrose, maltose, starch, silica gel, methanol (CH3OH), chloroform (CHCl3), sulphuric acid 
(H2SO4) (Merck chemicals (PTY) LTD, Wadeville, Gauteng, South Africa) and 
 
halothane (Isofor, Safeline Pharmaceuticals (Pty) Ltd, Roodeport, South Africa).  
All chemical reagents were of analytical grade.  
 
2.1   Isolation of OA and MA  
The extraction of OA and MA was performed in the Chemistry laboratory at UKZN 
Pietermaritzburg campus. These triterpenes were isolated from Syzygium aromaticum 
[(Linnaeus) Merrill & Perry] [Myrtaceae] flower buds using a previously validated standard 
protocol that has been reported from our laboratories (Mapanga et al., 2009; Musabayane et al., 
2010; Ngubane et al., 2011; Madlala et al., 2012; Mkhwanazi et al., 2014). Briefly, air-dried 
flower buds of S. aromaticum (500 g) were sequentially extracted twice at 24h intervals with 1 L 
of dichloromethane (DCM) and ethyl acetate (720 mL) on each occasion. The resulting filtrate 
was filtered using a 30 cm filter paper (Whatman, Maidstone, England). The filtrates were 
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concentrated in vacuo 60± 1
0
C using a laboratory 4000 efficient rotary evaporator (Laboratory 
Consumables and Chemical Supplies, Johannesburg, South Africa) to obtain DCM solubles (63 
g) and ethyl acetate solubles (EAS, 85 g). Crude EAS were subjected to further purification since 
previous studies indicated that they contain mixtures of OA/UA and methyl maslinate/methyl 
corosolate (Somova et al., 2003; Musabayane et al., 2005). The EAS containing mixtures of 
oleanolic/ursolic acid and methyl maslinate/methyl corosolate were purified by silica gel 60 
column chromatography with hexane: ethyl acetate solvent systems, 7:3 for OA and 6:4 for MA. 
This yielded OA and MA, respectively which were further purified by recrystallization from 
chloroform-methanol (1:1 v/v). The structures of these triterpenes were confirmed by 




C Nuclear Magnetic Resonance (NMR) 
techniques.  
Preliminary studies indicated that the properties of S. aromaticum-isolated OA and MA such as 
hypoglycemic effects were similar to respective commercial triterpenes and hence the plant-
extracted compounds were used in the experiments as they were less costly.  
 
 
2.2   Animals 
Male Sprague-Dawley rats weighing 250-300g bred and housed in the Biomedical Research Unit 
(BRU) of University of KwaZulu–Natal were used in this study. The animals were maintained 
under standard laboratory conditions of constant temperature (22±2 °C), CO2 content of <5000 
p.p.m., relative humidity of 55±5%, and illumination (12 h light/dark cycles) and the noise levels 
of <65 decibels and had free access to water and standard rat chow (Meadow Feeds, 
Pietermaritzburg, South Africa). Procedures involving animals and their care were conducted in 
conformity with institutional guidelines of the University of KwaZulu-Natal.  
 
2.3   Ethical consideration 
Ethical clearance was obtained from the University of KwaZulu-Natal Ethics committee 
(references: 082/11/Animal, 026/12/Animal, 056/13/Animal and 031/14/Animal see Appendices 
I, II, III and IV). 
40 
 
2.4   Induction of diabetes mellitus  
 
Experimental type 1 diabetes mellitus was induced in male Sprague-Dawley rats with the 
administration of a single intraperitoneal injection of 60 mg/kg streptozotocin (STZ) in freshly 
prepared 0.1 M citrate buffer (pH 6.3). The control animals were injected with the vehicle. 
Animals that exhibited glucosuria after 24 h, tested by urine strips (Rapidmed Diagnostics, 
Sandton, South Africa) were considered diabetic. Animals that showed blood glucose 
concentrations of 20 mmol/L or above, measured after one week were considered as having a 
stable diabetic state before experimental procedures.  
 
 
2.5   Experimental design  
The studies were divided into series I (in vitro) and series II (in vivo) experiments. The inhibitory 
activities of OA and MA against carbohydrate hydrolyzing enzymes were studied in vitro. The in 
vitro studies investigated the effects of OA and MA on glucose transport using the isolated small 
intestines. In vivo studies investigated the effects of OA/MA on postprandial blood glucose 
concentration, intestinal carbohydrate-hydrolyzing enzymes and glucose transporters (see Figure 































Figure 4: Flow diagram detailing acute in vivo studies carried out over a 2-hour period. Non-
diabetic and STZ-induced diabetic rats were loaded with mono-, di- and polysaccharides to 
observe the effects of triterpene treatments on blood glucose levels. This was in an effort to 
investigate the effects of the triterpenes on the intestinal carbohydrate hydrolyzing enzymes and 
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Figure 5: Flow diagram detailing sub-chronic in vivo studies carried out over a 5-week period. 
Non-diabetic and STZ-induced diabetic rats were maintained on a starch-based diet to observe 
the effects of triterpene treatments on blood glucose levels, food and water intake. Following the 
5-week study various biochemical parameters were investigated to elucidate the effects of the 
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These studies were carried out to investigate the effects of the triterpenes on carbohydrate 
hydrolyzing enzymes and intestinal glucose transport in vitro.  
 
2.6  In vitro assays  
2.6.1   Inhibitory enzyme assay studies  
To investigate the effects of OA and MA against enzymes such as α-amylase, α-glucosidase and 
sucrase, the inhibitory activities of these triterpenes were investigated in vitro. The inhibitory 
activities of OA and MA on α-amylase and α-glucosidase were studied using an α-amylase/α-
glucosidase-starch model system while inhibitory effects on sucrose utilized the dextran sucrase- 
dextran sucrose reaction mixture. 
 
2.6.2  α-amylase 
The assessment of the inhibitory effects of OA/MA against α-amylase activity in vitro was based 
on the modified method previously described by (Bhandari et al., 2008; Gao et al., 2009).. 
Briefly, soluble maize starch (1 mg) was boiled for 5 min in 0.5 mL of 0.5 M Tris-HCl buffer 
(pH 6.9) containing 0.01 M CaCl2. After cooling, deionized water was added to a final volume of 
100 mL. The solution was kept in the refrigerator and was used within 2-3 days. A reaction 
mixture of 500 μL containing 200 μL starch,  100 µL of OA/MA at various concentrations (4.37-
21.90 μmol/L) to which  200 μL of α-amylase (porcine pancreas, 2.60 mmol/L) was added to 
initiate the reaction and incubated at 37 
0
C for 37 min. The reaction was terminated by addition 
of 100 μL of 50% acetic acid. 
 
2.6.3   α-glucosidase 
The assessment of the inhibitory effects of OA and MA against α-glucosidase in vitro utilized a 
similar method described above for α-amylase except that the 0.1 M potassium phosphate buffer 
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(pH 6.9) was used. The assay mixture (500 µL) comprising of  200 µL of α-glucosidase (Type 1, 
Bakers yeast, 1.30 mmol/L) was premixed with OA/MA (100 µL) at various concentrations 
(4.37-21.90 μmol/L). The mixture was incubated at 37 °C for 30 min after adding starch in 
phosphate buffer and stopped by adding 1.5 mL of 2M Tris-HCl buffer (pH 6.9).  
 
2.6.4   Sucrase 
The in vitro sucrase inhibitory effects of OA/MA were performed as described above for α-
amylase except for that the assay mixture (700 µL) comprised of 200 µL dextran sucrose 
(56mmol/L) in the potassium phosphate buffer, 100 µL of OA/MA at various concentrations 
(4.37-21.90 μmol/L) and 400 μL of dextran sucrase (Leuconostoc mesenteroides, 2.60 mmol/L). 
In all cases, the liberated glucose was measured by the glucose oxidase method and the 
absorbance was recorded at 595nm using Varian Cary 1E UV-visible spectrophotometer (Varian 
Australia Pty Ltd, Victoria, Australia). Results expressed as the percentage inhibition of the 
corresponding control were calculated using the formula: 
 
   Abscontrol –AbssampleX 100 
% Inhibition =        
    Abscontrol 
 
Where Abscontrol was the absorbance without sample and Abssamples was the absorbance of sample 
extract. 
The IC50 values were calculated from plots of log concentration of inhibitor concentration versus 





2.7   Glucose transport in the small intestine   
To establish the effects of OA/MA on intestinal glucose transport, the everted intestinal sac 
technique described by Mahomoodally et al, was used in this study (Mahomoodally et al., 2006). 
Briefly, non-diabetic animals were rendered unconscious by a severe blow on the head against a 
hard surface after an 18-h fast. The whole small intestine was removed and rinsed with cold 
normal saline solution. Mid portions of the small intestine were removed by cutting across the 
upper end of the duodenum and the lower end of the ileum from the pyloric sphincter to the 
ileocecal junction and rinsed with cold normal saline solution (0.9%, w.v, NaCl). These intestinal 
segments (10±2 cm) were then everted according to the method previously described by Wilson 
and Wiseman (Wilson and Wiseman, 1954; Mahomoodally et al., 2005; Mahomoodally et al., 
2006). After weighing, the empty sac was filled with 1 ml of Krebs–Henseleit bicarbonate buffer 
(KHB composition in mmol/L: NaHCO3, 25; NaCl, 118; KCl, 4.7; MgSO4, 1.2; NaH2PO4, 1.2; 
CaCl2, 1.2; and Na2EDTA, 9.7 (serosal fluid), and tying the other end with a similar thread. The 
distended sac was immersed an organ bath containing 50 mL of KHB buffer incubation medium 
(mucosal fluid) which was continuously being bubbled with a mixture of 95% O2 and 5% CO2. 
The organ bath was surrounded by a water jacket maintained at 37±1 °C (see Figure 6).  
 
In separate preparations, 50µL  of 10mM d-glucose ( 500 µmol) was added to the medium just 
before the start of the experiments and incubated with graded concentrations OA/MA (0.82 - 
6.56 mmol/L) in the mucosal solution as shown in Figure 5. To establish whether OA or MA 
possess activities comparable to synthetic drugs already in use, studies were conducted in 
separate everted gut preparations incubated with phlorizin (a positive control for glucose uptake 




mmol/L) acted as untreated and treated positive controls, respectively. At the end of the 
incubation period (30 min), the sacs were removed from the organ bath, blotted and weighed 
again. The serosal fluid was drained through a small incision into a test tube. The emptied sac 
was shaken gently to remove the adhered fluid and the tissue was reweighed. The weight of the 
empty sac before and after the incubation did not significantly differ. The transport of d-glucose 
across the everted gut was evaluated by measuring the change in concentration of d-glucose 
inside and outside the intestinal sacs after 30 minutes of incubation. Mucosal glucose transfer is 
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the amount of glucose that disappeared from the mucosal fluid while serosal glucose uptake is 
the amount of glucose that entered the serosal fluid. Glucose concentration was measured using a 
commercial glucose oxidase kit (Boenhringer Mannheim, Germany). In this protocol, glucose is 
oxidized to gluconic acid and hydrogen peroxide by glucose oxidase. Hydrogen peroxide reacts 
with o-dianisidine in the presence of peroxidase to form a coloured product. The oxidized o-
dianisidine reacts with sulphuric acid to form a more stable pink-coloured product. The intensity 
of this colour is measured at 540nm and this is proportional to the glucose concentration. All 
samples were read in a Novaspec II spectrophotometer against a blank. A standard curve was 
obtained after measuring the absorbance of standards of glucose which were prepared in the 
range of 5.5-22.2 mmol/L. Using absorbances obtained from the spectrophotometer, glucose 
concentration was then extrapolated from this standard curve and the results obtained were 






Figure 6. The everted intestinal sac protocol developed by Wilson and Wiseman (Wilson and 
Wiseman, 1954). This technique measures the influence of drugs on intestinal glucose uptake by 
measuring glucose concentrations in the mucosal and serosal fluid before and after the 30-minute 










Series II  
These studies were carried out to investigate the effects of the triterpenes on intestinal 
carbohydrate handling in vivo in non-diabetic and STZ-diabetic animals. These were subdivided 
into oral glucose tolerance (OGT) responses and sub-chronic studies.  
 
2.8   Oral glucose tolerance (OGT) responses 
In order to determine how the small intestine handles different types of carbohydrates, non-
diabetic and STZ-induced diabetic animals were loaded with monosaccharides, disaccharides 
and polysaccharides.  Oral glucose tolerance responses were monitored in these animals as 
previously described by our laboratory with slight modifications (Mapanga et al., 2009; 
Musabayane et al., 2010). The rats were divided into the following groups: control and treated 
non-diabetic rats as well as control and treated STZ-induced diabetic rats (n = 6 in each group). 
After an 18 h fasting period, glucose was measured (time 0) followed by loading with 
monosaccharide (glucose; 0.86 g/kg, p.o.), disaccharide (sucrose; 1.72 g/kg, p.o.) or 
polysaccharide (starch; 0.086 g/kg, p.o.) delivered into the stomach by a gavage needle (18-
gauge, 38 mm long curved, with a 21/4 mm ball end (Able Scientific, Canning Vale, Australia). 
The selection of these doses was based on previous studies conducted in our laboratory 
(Musabayane et al., 2006; Gondwe et al., 2008; Musabayane et al., 2010). In order to determine 
the effects of triterpenes on postprandial glucose, separate groups of non-diabetic and STZ-
induced diabetic rats were administered OA and MA (80 mg/kg, p.o.) dissolved in dimethyl 
sulphoxide and deionized water. Rats treated with DMSO/water (3 mL/kg, p.o.) and standard 
drugs acarbose (100mg/kg, p.o.), insulin (175µg/kg, sc) and phlorizin (100mg/kg, p.o.) served as 
untreated and positive controls, respectively (Mapanga et al., 2009; Musabayane et al., 2010; 
Ngubane et al., 2011). Blood glucose concentrations were measured using the tail-prick method 
with the use of a OneTouch select glucometer (Lifescan, Mosta, Malta, United Kingdom) were 
made at 15, 30, 60, and 120 minutes after carbohydrate loading (see Figure 3). The area under 
the curve (AUC) for increase in glucose over baseline was calculated during OGT responses by 
the incremental method that calculates changes in blood glucose concentrations relative to the 
beginning of the experiment.  
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2.9   Intestinal glucose handling 
To assess the influence of OA and MA on intestinal glucose handling, the activity of intestinal 
carbohydrate hydrolyzing enzymes and glucose transporters, groups of non-diabetic and STZ-
induced diabetic male Sprague-Dawley rats were housed individually in Makrolon polycarbonate 
metabolic cages (Techniplast, Labotec, South Africa) for a 5-week period (n=6 in each group).  
In those animals in which the effects of OA/MA were investigated, the rats were administered 
with OA/MA (80 mg/kg, p.o.) twice daily at 09h00 and 15h00 by means of an oral gavage needle 
(18-gauge, 38 mm long curved, with a 21/4 mm ball end (Able Scientific, Canning Vale, 
Australia). Rats treated with DMSO/saline (3 mL/kg, p.o.) served as untreated controls while 
those treated with standard anti-diabetic drugs metformin (500 mg/kg, p.o.) and insulin (175 
µg/kg  sc) served as treated positive controls (see Figure 4). Body weight changes as well as food 
and water intake were assessed every third day at 09h00 for the duration of the experimental 
period. At the end of the 5 week experimental period, the animals were killed by exposing to 
halothane (100 mg/kg, for 3 min) (Isofor, Safeline Pharmaceuticals (Pty) Ltd, Roodeport, South 
Africa) via a gas anaesthetic chamber (Biomedical Resource Unit, UKZN, Durban, South 
Africa). 
  
2.10   Tissue sample harvesting  
Blood was collected by cardiac puncture from groups of untreated non-diabetic and STZ-induced 
diabetic as well as treated STZ-induced diabetic rats into individual pre-cooled heparinized 
containers at the end of the 5-week experimental period. The blood was centrifuged (Eppendorf 
centrifuge 5403, Germany) at 4 °C and a speed of 503 g for 15 minutes and separated plasma 
was stored at -70 °C in a Bio Ultra freezer (Snijers Scientific, Holland) for hormonal assays that 
are described in section 2.11. Thereafter, the whole of the small intestine was removed by cutting 
across the upper end of the duodenum and the lower end of the ileum from the pyloric sphincter 
to the ileocecal junction and rinsed with cold normal saline solution. Mid portions of the small 
intestine were snap frozen in liquid nitrogen and stored in a BioUltra freezer (Snijers Scientific, 
Tilburg, Netherlands) at -70 °C for Western blot analysis of glucose transporters (SGLT1 and 
GLUT2),  carbohydrate hydrolyzing enzymes (α-amylase and α-glucosidase) and ghrelin 
expression. The stomach and large intestine were also removed, snap frozen in liquid nitrogen 
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and stored at -70
0
C for Western blot analysis for ghrelin. Other mid portions of the small 
intestine were placed in formalin and stored at room temperature (22
0
C) for histological analysis. 
These procedures will be discussed in more detail in later sections. 
 
 
2.11   Laboratory analyses  
2.11.1   Intestinal glycogen concentration 
The glycogen concentration was measured in mid portion segments of the small intestine of 
starved and non-starved non-diabetic and STZ-induced diabetic rats with access to water 18-h 
after treatment with OA and MA (80 mg/kg p.o.) while those obtained from the metformin- 
treated (500 mg/kg p.o.) and insulin-treated (175µg/kg sc) served as positive controls. The 
animals were rendered unconscious by a severe blow to the head against a hard surface. The 
glycogen concentration was determined using a previously validated protocol with modifications 
(Ong and Khoo, 2000; Ngubane et al., 2011). Briefly, the tissue samples (0.5- 0.7 g) were 
homogenized in 2 mL of 30% KOH solution and digested at 100°C for 30 min and then cooled 
in ice saturated sodium sulphate. The glycogen was precipitated with ethanol, and then pelleted, 
washed, and redissolved in deionized water. Glycogen standards (10-2000 mg/L) were also 
prepared using glycogen powder. The glycogen concentration was determined by its reaction 
with the anthrone reagent [2 g anthrone/ 1 of 95% (v:v) H2SO4] after which absorbance was 









2.11.2   Hormone measurements 
2.11.2.1   Insulin  
 
Plasma insulin concentrations were measured using an ultra-sensitive rat insulin ELISA kit 
(DRG diagnostics EIA-2746 GmbH, Marburg, Germany) in untreated non-diabetic and STZ-
induced diabetic controls as well as the STZ-diabetic treated groups. The kit contained a 96 well 
plate coated with mouse monoclonal anti-insulin, standards, enzyme conjugate, enzyme 
conjugate buffer, wash buffer, substrate 3,3',5,5'-tetramethylbenzidine (TMB) and a stop 
solution. The principle of the assay is a solid phase two-site enzyme immunoassay based on the 
direct sandwich technique in which two monoclonal antibodies are directed towards separate 
antigenic determinants antigenic epitopes of insulin. During the incubation period, insulin in the 
sample reacts with the peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies 
bound to the microtitration well. The washing step removes all unbound enzyme labeled 
antibody, leaving only the bound conjugate which reacts with TMB. This reaction is stopped by 
adding acid to give a colorimetric endpoint that is read spectrophotometrically. Each 
determination was performed in duplicate for standards and samples. The insulin assay 
procedure was as follows: 50µL of each insulin standard (20.0, 50.0, 150.0, 400.0 and 1000.0 
pmol/L) were added to anti-insulin wells. 50µL of the plasma samples were then added to the 
remaining wells followed by 50µL enzyme conjugate to all wells of standards and plasma 
samples. The plates were incubated at room temperature for 2 hours on a plate shaker 
(VelpScientifica, Milano, Italy) followed by aspirating the reaction volume, adding wash buffer 
(350 µL) and aspirating 6 times. After the final wash the plates were inverted firmly against 
absorbent paper to absorb all the liquid in the plates. 200 µL substrate TMB was added to all the 
wells and incubated for 30 minutes. The reaction was stopped by adding 50µL of stop solution to 
all wells and mixing on a shaker for 5minutes. The absorbance was measured at 450 nm using a 
Biotekmicroplate reader (Winooski, Vermont, USA). A standard curve was constructed from the 
absorbance values of the known concentrations of the standards using the spline regression curve 
in GraphPad Instat software (version 5.00). The respective insulin concentrations of the unknown 
samples were then extrapolated from the standard curve. The lower and upper limits of detection 
were 1.39 pmol/L and 960 pmol/L, respectively. The intra-assay analytical coefficient of 
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variation ranged from 4.4 to 5.5% while the inter-assay coefficient variation ranged from 4.7 to 
8.9%.  
 
2.11.2.2   Ghrelin  
In order to evaluate the effects of treatment with OA and MA on ghrelin secretion, plasma 
ghrelin was measured using ultra-sensitive rat ghrelin ELISA kit (DRG diagnostics EIA-3706 
GmbH, Marburg, Germany) in untreated non-diabetic and STZ-induced diabetic controls as well 
as the STZ-diabetic treated groups. The kit contained a 96 well plate pre-coated with secondary 
antibody and the nonspecific binding sites are blocked. The secondary antibody can bind to the 
Fc fragment of the ghrelin antibody whose Fab fragment will be competitively bound by 
biotinylated ghrelin in sample. The biotinylated peptide is able to interact with streptavidin-
horseradish peroxidase (SA-HRP) which catalyzes the substrate solution composed of  3,3’, 5,5’-
tetramethylbenzidine (TMB) and hydrogen peroxidase to produce a blue colored solution. The 
enzyme-substrate reaction is stopped by hydrogen chloride (HCl) and the solution turns to 
yellow. The intensity of the yellow is directly proportional to the amount of biotinylated peptide-
SA-HRP complex but inversely proportional to the amount of the peptide in standard solutions or 
samples. This is due to the competitive binding of the biotinylated ghrelin and the ghrelin in 
standard solutions or in the  samples to the ghrelin antibody. A standard curve of ghrelin with 
known concentrations was established accordingly. The concentration of ghrelin in samples was 
determined by extrapolation from the standard curve. The lower and upper limits of detection 
were 0.1 pmol/L and 960 pmol/L, respectively. The intra-assay analytical coefficient of variation 









2.11.3  Western blot analysis 
In order to further elucidate the mechanism of the triterpenes, we investigated the gastrointestinal 
expression of ghrelin, carbohydrate hydrolyzing enzymes and glucose transporters using Western 
blot analysis. Small intestine tissues obtained from untreated non-diabetic and STZ-induced 
diabetic controls as well as the STZ-diabetic treated groups (0.1 g) were homogenized on ice in 
isolation buffer (0.5 mM Na2EDTA, 0.1 M KH2PO4, 0.1 mM dithiothreitol, 0.25 M sucrose) and 
then centrifuged at 400 x g for 10 min (4 
°
C). The protein content was quantified using the 
Lowry method (Lowry et al., 1951). The Lowry method involves reaction of protein with cupric 
sulphate and tartrate in an alkaline solution, resulting in formation of tetradentate copper-protein 
complexes. When the Folin-Ciocalteu reagent is added, this reagent is effectively reduced in 
proportion to these chelated copper complexes, producing a water-soluble product whose blue 
color can be measured at 750 nm. Upon completion of protein quantification, all the samples 
were standardized to one concentration (1 mg/mL). The proteins were then denatured by boiling 
in Laemmli sample buffer (0.5 M Tris-HCl, glycerol, 10% sodium dodecyl sulphate (SDS), 2-
mercaptoethanol, 1% bromophenol blue for 5 min. The denatured proteins were loaded (25 µL) 
on prepared resolving (10%) and stacking (4%) polyacrylamide gels along with molecular 
weight marker (5 µL). The gel was electrophoresed for 1 h at 150 V in electrode (running) buffer 
(Trisbase, glycine, SDS), pH 8.3). Following electrophoresis, the resolved proteins were electro-
transferred to an equilibrated polyvinylidenedifluoride (PVDF)/ membrane for 1 h in transfer 
buffer (192 mM glycine, 25 mMtris, 10% methanol). After transfer, the membrane was blocked 
with 5% non-fat dry milk in Tris-buffered saline with 0.1% Tween 20 (TTBS) (20 mM tris, 150 
mM NaCl, KCl, 0.05% Tween-20). The membrane was then immuno-probed with antibodies- 
glycogen synthase (1:1 000 in 1% BSA, Neogen, USA) for 1 h at room temperature (RT); α-
amylase and α-glucosidase (1:500 in 1% BSA, Neogen, USA); SGLT1 and GLUT2 (1:1 000 in 
1% BSA, Neogen, USA) and ghrelin (1:1000 in 1% BSA, Neogen, USA) for 1 h at room 
temperature (RT). The PVDF membrane was then subjected to 5 washes (10 min each with 
gentle agitation) with TTBS.  Following which, the membrane was incubated in horse radish 
peroxidase (HRP)-conjugated secondary antibody (rabbit anti-mouse 1:1000; Bio-Rad) for 1 h at 
RT. After further washing, antigen-antibody complexes were detected by chemiluminescence 
using the Immune-star  HRP substrate kit (Bio-Rad, Johannesburg, South Africa). 
Chemiluminescent signals were detected with the Chemi-doc XRS gel documentation system 
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and analysed using the quantity one software (Bio-Rad, Johannesburg, South Africa). Band 
intensity analysis was conducted on the resultant bands.  
 
 
2.12  Oxidative stress  
To determine the effects of OA and MA on oxidative stress, e compared levels of 
malondealdehyde (MDA), a known marker of oxidative stress and of antioxidant defense 
enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx) in non-diabetic, 
untreated STZ-diabetic and STZ-diabetic treated groups following the sub-chronic study.  
 
2.12.1   MDA  
 
The effects of the triterpenes on oxidative stress were investigated by assessing malondealdehyde 
(MDA) concentrations. Small intestine tissues (50 mg) were homogenized in 500 mL of 0.2% 
phosphoric acid. The homogenate was centrifuged at 400 g for 10 min. 400 mL of the 
homogenate was supplemented with 400 mL 2% phosphoric acid and then separated into two 
glass tubes, each receiving equal volumes of the solution. Thereafter, 200 mL of 7% phosphoric 
acid was added into both glass tubes followed by the addition of 400 mL of thiobarbituric acid 
(TBA)/butylated hydroxytoluene (BHT) into one glass tube (sample test) and 400 mL of 3mM 
hydrochloric acid (HCl) into the second glass tube (blank). To ensure an acidic pH of 1.5, 200 
mL of 1M HCl was added to sample and blank test tubes. Both solutions were heated at 100 
0
C 
for 15 min, and allowed to cool to room temperature. Butanol (1.5 mL) was added to the cooled 
solution; the sample was vortexed for 1 min to ensure rigorous mixing and allowed to settle until 
two phases could be distinguished. The butanol phase (top layer) was transferred to Eppendorf 
tubes and centrifuged at 13,200g for 6 min. The samples were aliquoted into a 96-well Microtiter 
plate in triplicate and the absorbance was read at 532 nm (reference 600 nm) on a 
BioTekmQuant spectrophotometer (Biotek, Johannesburg, South Africa). The absorbance from 





      Average absorbance 
Concentration of MDA (mM) =        




2.12.2   SOD  
 
The antioxidant effects of OA and MA were determined in small intestine samples collected after 
the 5-week study by assessing superoxide dismutase (SOD) activity. SOD activity was assessed 
by measuring the dismutation of superoxide radicals generated by xanthine oxidase and 
hypoxanthine in a convenient 96 well format. SOD activity was measured using the Biovision 
SOD Assay Kit according to manufacturers’ instructions (BioVision Research Products, 
Mountain View, CA). Small intestine tissues (50 mg) were homogenized in ice cold 0.1 M 
Tris/HCl (pH 7.4) containing 0.5% Triton X-100, 5mM β-mercaptoethanol (ME) and 0.1 mg/mL 
1 phenyl methane sulphonylonyl fluoride (PMSF). The tissue homogenate was centrifuged at 
14,000g for 5 min at 4 
0
C. The supernatant obtained was added to each sample (20 mL) and 
blank 2 (20 mL) well, while blank 1 and blank 3 wells received 20 mL of H2O. Thereafter, 200 
mL of working solution was added to each well. Subsequently, dilution buffer (20 mL) was 
added to each blank 2 and blank 3 well, while each sample and blank 1 well received enzyme 
working solution (20 mL). The solutions were mixed thoroughly before reading the plate. 
Inhibition activity of SOD was colorimetrically measured on an Anthos Venytch-200 
Spectrophotometer (Biochrom limited, Cambridge, United Kingdom) after a reaction period of 
20 min at 37 
0
C. SOD activity was calculated as percentage inhibition using the equation:  
      
 
(Ablank1 _ Ablank3) - _ (Asample _ Ablank2) 
SOD activity (%inhibition rate) =         





2.12.3   Glutathione peroxidase (GPx)  
To further investigate the antioxidant properties of OA and MA, their effects were determined in 
small intestine samples collected after the 5-week study by assessing glutathione peroxidase 
(GPx) activity. GPx is an antioxidant enzyme which reduces liquid hydroperoxides to their 
corresponding alcohols and hydrogen peroxide to water through the oxidation of reduced 
glutathione to oxidized glutathione. GPx activity was measured in rat small intestine tissues 
using the Biovision GPx Assay Kit according to manufacturers’ instructions (BioVision 
Research Products, Mountain View, CA). Briefly, the tissues (50 mg) were homogenized on ice 
in cold assay buffer (0.2 mL) and subsequently centrifuged at 10,000g for 15 min at 4 
0
C. The 
resultant supernatant (100 mL) was loaded into a 96-well plate in duplicate. The NADPH 
standard curve was prepared by diluting the 1mM NADPH standard through a series of 
concentrations (0, 20, 40, 60, 80, 100 nmol per well). The optical density of the standards (OD) 
was measured at 340 nm using an Anthos Venytch-200 Spectrophotometer (Biochrom Limited, 
Cambridge, United Kingdom) and the standard curve was constructed from the values obtained. 
A reaction mix (90 mL) containing assay buffer, NADPH, glutathione reductase and GSH was 
added into each sample well, mixed thoroughly and incubated for 15 min at room temperature. 
The OD was then measured (340 nm) followed by the addition of cumene hydroperoxide (10 
mL) and measurement of OD (T1) and another reading following a 5 min incubation in the dark 
(25 
0
C). GPx activity was calculated using following equation:  
 
 
   B  -  B
0
  X  Sample dilution  
GPx activity =       
(T2 - T1)X V 
where ΔA340nm was used to extrapolate the values of B and B
0 





2.12.4   Histological studies 
In order to determine if the treatment of rats with OA and MA induced any morphological 
changes in the small intestine, histological analysis was used. Following the sub-chronic study, 
small intestine tissues were stored in 10% formalin immediately after killing the non-diabetic 
control, STZ-induced diabetic control, as well as the STZ-diabetic animals treated with OA, MA, 
metformin as well as insulin. The tissues were cut in the longitudinal as well as cross-section 
manner using a sterile blade. The tissues were then rinsed with water to remove excess formalin 
and then placed in 70%, 80%, 90%, as well as 100% ethanol for 2, 2, 3 and 2 minutes, 
respectively. During this process, the water within the tissue is replaced with alcohols of varying 
strengths to facilitate dehydration. The tissue was then placed in xylene that clears the alcohol 
and leaves the tissue translucent. The tissues were embedded in wax blocks which are then 
sectioned at a thickness of 4microns using a Microm rotary microtome (Robert-Bosch-Strabe, 
Walldorf, Baden-Wurttemburg, Germany). The tissue sections were mounted onto clean slides 
and placed onto a Ransom warming plate to allow for drying. The sections were then de-
paraffinized with xylene and stained with the haematoxylin and eosin stain (Sigma-Aldrich, St 
Louis, Missouri, USA). The section was then permanently mounted with a drop of mounting 
medium and covered with a coverslip. The slides were then scanned with a Leica scanner SCN 
400 (Leica Microsystem CMS, GmbH, Ernst-Leitz-Strasse, Wetzlar, Germany).   
 
2.13  Analysis of data 
All data were expressed as means ± S.E.M. Statistical comparisons between control and treated 
groups were performed with GraphPadInStat Software (version 5.00, GraphPad Software, Inc., 
San Diego, California, USA) using one-way analysis of variance (ANOVA) followed by Tukey- 










3.0  Structure elucidation  




C NMR techniques.  
 
3.1  OA  
The purity of the S. aromaticum-derived OA (see Figure 7) determined by 
1
H NMR and 
13
C 
NMR (1D and 2D) was approximately 98% and the percentage yields varied from 0.79% to 
1.72%. The 
1
H NMR and 
13
C NMR (1D and 2D) given below was obtained.  
1
H NMR CDCl3 δ, 0.73, 0.75, 0.88, 0.89, 0.90, 0.96, 1.11 (each 3H, s), 2.84 (
1
H, dd, J = 10.36), 
3.22 (
1
H, dd, J = 4.56, 5.26 (
1
H, t, J = 3.76);  
13
C NMR (CDCl3) : δ 183.5, 143.8, 122.7, 79.2, 55.4, 47.8, 46.8, 46.1, 41.8, 41.2, 39.5, 38.9, 
38.6, 38.3, 34.0, 33.3, 32.8, 32.7, 31.6, 28.4, 27.9, 27.4, 26.2, 23.8, 23.7, 23.1, 18.5, 17.4, 15.8, 
15.5.  




































Figure 8. Syzygium aromaticum-derived OA 
1
H (A) and 
13
C NMR (B) spectroscopic data. Pure 














 3.2   MA  




C NMR (1D 





C NMR (1D and 2D) given below was obtained.   
13
C NMR: δH (
13
CNMR (400 MHz,CD3OD): 46.2 (C-1), 68.3 (C-2), 83.3 (C-3),39.1 (C-4), 55.0 
(C-5), 18.1 (C-6), 32.7 (C-7), 39.0 (C-8), C-9(47.4), C-10 (38.0), C-11 (23.2), C-12 (121.9), C-
13 (143.7),C-14 (41.6), C-15 (27.4), C-16 (23.0), C-17 (46.2), C-18(41.0), C-19 (45.7), C-20 
(30.4), C-21 (33.6), C-22 (32.3),C-23 (28.3), C-24 (16.6), C-25 (16.5), C-26 (16.4), C-27(23.2), 
C-28 (178.5), (C-29) 32.2, C-30 (23.2). 
























































Figure 10. Syzygium aromaticum-derived MA 
1
H (A) and 
13
C NMR (B) spectroscopic data. Pure 
















Series I  
Series I studies were carried out to investigate the effects of OA and MA on carbohydrate 
hydrolyzing enzymes and intestinal glucose transport in vitro using the enzyme-carbohydrate 
model system and the everted intestinal sacs technique, respectively.  
 
3.3   Carbohydrate hydrolyzing enzyme activity  
 
The effects of OA and MA on key intestinal carbohydrate hydrolyzing enzymes were performed 
using in vitro assays to assess the inhibitory activities of the triterpenes against these enzymes. 
The inhibitory activities of OA and MA on intestinal α-glucosidase/α-amylase were studied 
using an α-glucosidase/α-amylase starch model system while inhibitory effects on sucrose 
utilized the dextran sucrase- dextran sucrose reaction mixture. The IC50 values of the triterpenes 
were calculated from plots of log concentration of inhibitor concentration versus percentage 
inhibition curves. Table 3 shows that OA and MA displayed inhibitory effects on the activity of 
sucrase, α-glucosidase and α-amylase as these triterpenes were found to possess IC50 values 
comparable with those of the standard drug acarbose.  
 
Table 3: IC50 values of OA, MA and acarbose on the activities of  sucrase, α-glucosidase and α-
amylase in vitro. Values are presented as means ± SEM (n=4 in each group).  
 
IC50 (µg/mL) 
 Sucrase α- glucosidase α-amylase 
OA 59.74 ± 1.76 55.45 ± 1.75 62.11 ± 1.80 
MA 60.91 ± 4.91 57.61 ± 3.08 71.01 ± 1.85 







3.4   Glucose transport in the everted gut  
The effects of OA and MA on intestinal d-glucose absorption (mucosal glucose transfer) and 
transport across the everted gut (serosa glucose uptake) across rat everted small intestinal sacs 
are shown in Figures 11 and 12.  
 
The amount of glucose in the mucosal fluid was significantly (p<0.05) reduced throughout the 
30-minute incubation period in the control everted intestinal sacs by comparison to the initial 
amount of glucose in the mucosa. This was accompanied by a simultaneous steady appearance of 
glucose in the serosa. Both OA and MA at a low concentration (0.82 mmol/L) had no significant 
effect on mucosal glucose disappearance and serosa glucose disappearance. However, OA and 
MA at concentrations ranging from 1.64 - 6.56 mmol/L significantly (p<0.05) suppressed 
mucosal glucose disappearance and serosa glucose appearance in a dose-independent manner. A 












































































Figure 11. Effects of graded concentrations of OA (0.82 - 6.56 mmol/l) on mucosal glucose 
disappearance and serosa glucose appearance in rat everted intestinal sacs. The initial amount of 
glucose in the mucosal fluid was 500 μmol indicated by the horizontal line. Values are presented 
as means, and vertical bars indicate SEM of means (n=6 for each concentration). ♦=p<0.05 by 


































































Figure 12. Effects of graded concentrations of MA (0.82 - 6.56 mmol/l) on mucosal glucose 
disappearance and serosa glucose appearance in rat everted intestinal sacs. The initial amount of 
glucose in the mucosal fluid was 500 μmol indicated by the horizontal line. Values are presented 
as means, and vertical bars indicate SEM of means (n=6 for each concentration). ♦=p<0.05 by 











































































Figure 13. Effects of graded concentrations of phlorizin on mucosal glucose disappearance and 
serosa glucose appearance in rat everted intestinal sacs. The initial amount of glucose in the 
mucosal fluid was 500 μmol indicated by the horizontal line. Values are presented as means, and 
vertical bars indicate SEM of means (n=6 for each concentration). ♦ = p<0.05 by comparison to 












Series II studies were subdivided into influences on postprandial blood glucose as assessed by 
oral glucose tolerance (OGT) responses over two hours (acute) following loading with various 
carbohydrates and sub-chronic studies carried out over 5-weeks where the rats were kept on 
standard rat chow.  
 
3.5 Acute effects 
3.5.1 OGT responses 
OGT responses to OA and MA (80 mg/kg) were monitored in separate groups of non-diabetic 
and STZ-induced diabetic rats following glucose (0.86 g/kg, p.o.), sucrose (1.72 g/kg, p.o.) and 
starch (0.086 g/kg, p.o.) loading after an 18-h fast. 
Blood glucose concentrations were significantly (p<0.05) higher in untreated STZ-induced 
diabetic rats loaded with glucose, sucrose and starch at time 0 during the OGT response tests 
compared to the control non-diabetic rats. Following the loading of glucose, sucrose and starch, 
the blood glucose concentration of control non-diabetic and untreated STZ-induced diabetic rats 
increased for 60 minutes before declining to blood glucose concentrations comparable with those 
at time 0 by the end of the 2 h experimental period. Administration of OA and MA had no 
significant effects on the blood glucose concentration in glucose, sucrose and starch-loaded non-
diabetic rats. This was further shown by a lack of significant changes in the AUC values in the 
OA and MA-treated rats by comparison with the non-diabetic control. However, the blood 
glucose concentrations in OA and MA-treated STZ-diabetic rats persisted declining below the 
preloading values by the end of the 2 h experimental period. This was accompanied by 
significant (p<0.05) reductions in the AUC values of the STZ-diabetic OA and MA-treated rats 
loaded with the various carbohydrates (see Figures 14, 15 and 16). A similar response pattern of 
results was observed in glucose-loaded STZ-diabetic rats treated with phlorizin (100 mg/kg, p.o.) 
and sucrose or starch-loaded STZ-diabetic rats treated with acarbose (100 mg/kg, p.o.) (see 




















































Figure 14. Comparison of OGT responses to OA and MA in non-diabetic and STZ-diabetic rats 
with control non-diabetic, untreated STZ-diabetic and those treated with the standard drug 
phlorizin following a glucose load. Values are presented as means, and vertical bars indicate 
SEM of means (n = 6 in each group). ♦=p<0.05 by comparison to the non-diabetic control.   















































Figure 15. Comparison of the AUCglucose values obtained from OGT responses to OA and MA in 
non-diabetic and STZ-diabetic rats with control non-diabetic, untreated STZ-diabetic and those 
treated with the standard drug phlorizin following a glucose load. The AUCglucose was calculated 
by incremental method. Values are presented as means, and vertical bars indicate SEM (n = 6 



















































Figure 16. Comparison of OGT responses to OA and MA in non-diabetic and STZ-diabetic rats 
with control non-diabetic, untreated STZ-diabetic and those treated with the standard drug 
phlorizin following a sucrose load. Values are presented as means, and vertical bars indicate 
SEM of means (n = 6 in each group). ♦=p<0.05 by comparison to the non-diabetic control.   

















































Figure 17. Comparison of the AUCglucose values obtained from OGT responses to OA and MA  in 
non-diabetic and STZ-diabetic rats with control non-diabetic, untreated STZ-diabetic and those 
treated with the standard drug acarbose following a sucrose load.  The AUCglucose was calculated 
by incremental method. Values are presented as means, and vertical bars indicate SEM (n = 6 



















































Figure 18. Comparison of OGT responses to OA and MA in non-diabetic and STZ-diabetic rats 
with control non-diabetic, untreated STZ-diabetic and those treated with the standard drug 
phlorizin following a starch load. Values are presented as means, and vertical bars indicate SEM 
of means (n = 6 in each group). ♦=p<0.05 by comparison to the non-diabetic control.   =p<0.05 








































Figure 19. Comparison of the AUCglucose values obtained from OGT responses to OA and MA in 
non-diabetic and STZ-diabetic rats with control non-diabetic, untreated STZ-diabetic and those 
treated with the standard drug acarbose following a starch load.  The AUCglucose was calculated 
by incremental method. Values are presented as means, and vertical bars indicate SEM (n = 6 




3.6  Sub-chronic effects 
3.6.1   Physicochemical changes  
3.6.1.1  Body weight changes, food and water intake  
Non-diabetic control rats progressively gained weight while STZ-induced diabetic rats exhibited 
severe weight loss throughout the experimental period. Treatment of the STZ-diabetic rats with 
OA and MA (80 mg/kg, p.o.) significantly (p<0.05) increased the body weights of STZ-induced 
diabetic rats from the third week to the fifth week by comparison with the STZ-diabetic control 
rats. A similar trend was observed in those rats treated with the standard drugs metformin (500 
mg/kg, p.o.) and insulin (175 µg/kg, p.o.).  
 
The daily food and water intake of STZ-induced diabetic control rats significantly (p<0.05) 
increased by comparison to the non-diabetic control over the 5-week period. On the contrary, 
STZ-diabetic rats treated with OA and MA (80 mg/kg, p.o.) showed significant (p<0.05) 
decreases in food intake by comparison to the STZ-induced diabetic controls from the third week 
onwards. A similar response pattern of results was observed in those rats treated with the 
















Table 4: Comparison of the effects of OA and MA administered in STZ-diabetic rats twice every 
third day for 5 weeks on body weight changes, food and water intake with control non-diabetic, 
untreated STZ-diabetic rats and those treated with the standard drugs metformin and insulin (n=6 
in each group). Values are presented as means ± SEM.  














 16.0 ± 0.5
♦
 16.0 ± 0.4
♦
 16.0 ± 0.5
♦
 16.0 ± 0.5
♦
 
STZ-OA  14.1 ± 1.8
♦
 13.9 ± 2.2
♦
 12.4 ± 1.8* 11.3 ± 1.6* 11.2 ± 1.4* 
STZ-MA 14.0 ± 1.4
♦
 14.1 ± 1.6
♦
 12.6 ± 2.
 
0* 11.4 ± 1.8* 11.2 ± 1.5* 
STZ-Met  13.5 ± 1.6
♦
 13.0 ± 1.8
♦
* 12.1 ± 1.6* 12 ± 1.2* 11.5 ± 1.8* 
STZ-Ins 13.8 ± 1.2
♦
 13.2 ± 2.0
♦













 40.0 ± 3.0
♦
 48.0 ± 2.0
♦
 48.0 ± 3.0
♦
 48.0 ± 3.4
♦
 
STZ-OA  36.0 ± 1.7
♦
 36.0 ± 2.4
♦
 35.0 ± 1.4
♦
* 34.0 ± 1.9
♦
* 32.0 ± 1.6
♦
* 
STZ-MA 38.0 ± 2.1
♦
 36.0 ± 3.0
♦
 36.0 ± 1.9
♦
* 34.0 ± 2.7
♦
* 32.0 ± 1.9
♦
* 
STZ-Met  36.0 ± 1.9
♦
 34.0 ± 1.8
♦
* 32.0 ± 3.1
♦
* 32.0 ± 2.5
♦
* 30.0 ± 2.0
♦
* 
STZ-Ins 36.0 ± 2.0
♦
 34.0 ± 1.7
♦
* 32.0 ± 2.0
♦
* 30.0 ± 3.2
♦


















 -1.4 ± 0.2
♦
 -2.4 ± 0.5
♦
 -4.0 ± 0.3
♦
 -6.4 ± 0.7
♦
 
STZ-OA  1.1 ± 0.3
♦
 1.0 ± 0.4
♦
* 1.9 ± 5.7
♦
* 3.2 ± 0.5
♦
* 3.4 ± 0.6
♦
* 
STZ-MA 1.2 ± 0.4
♦
 1.0 ± 0.3
♦
 1.6 ± 0.5
♦
* 1.6 ± 0.2
♦
* 1.7 ± 0.7
♦
* 
STZ-Met  1.0 ± 0.3
♦
 1.4 ± 0.4
♦
 2.4 ± 0.1
♦
* 2.6 ± 0.8
♦
* 4.2 ± 0.2
♦
* 
STZ-Ins 1.6 ± 0.7
♦
 1.6 ± 0.4
♦
 2.4 ± 0.7
♦
* 3.2 ± 0.4
♦
* 3.2 ± 0.3
♦
* 
♦=p<0.05 by comparison to the non-diabetic control. *=p<0.05 by comparison to the STZ-
diabetic control.  
77 
 
3.6.1.2  Blood glucose concentrations 
Figure 20 shows the sub-chronic effects of treatment of STZ-diabetic rats with OA and MA (80 
mg/kg, p.o.) on blood glucose concentrations measured throughout the 5-week experimental 
period.  Untreated STZ-diabetic rats showed significantly (p<0.05) increased blood glucose 
concentrations by comparison with non-diabetic rats for the duration of the 5-week experimental 
period. On the other hand, STZ-diabetic rats treated with OA and MA (80 mg/kg, p.o.) showed 
significant (p<0.05) reductions in blood glucose concentrations from the first week by 
comparison to the STZ-induced diabetic control rats. These concentrations gradually decreased 
throughout the experimental period to levels comparable with those of the non-diabetic control 
animals by the fifth week of the study.  STZ-diabetic rats treated with insulin (175 µg/kg, sc) or 





















































Figure 20. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on blood glucose concentration with untreated STZ-diabetic rats and 
those treated with the standard drugs metformin and insulin. Values are presented as means, and 
vertical bars indicate SEM of means (n = 6 in each group).♦ =p<0.05 by comparison to the non-











3.7  Intestinal glycogen concentrations  
To establish the effects of OA and MA on intestinal glycogen synthesis, intestinal glycogen 
concentrations were measured in separate groups of non-diabetic control, untreated STZ-diabetic 
and STZ-diabetic treated rats following the 5-week study.   
 
The small intestine glycogen concentrations of STZ-induced diabetic rats were significantly 
(p<0.05) decreased by comparison with those of the non-diabetic rats after the 5-week 
experimental period. On the other hand, treatment of STZ-induced diabetic rats with OA and MA 
significantly (p<0.05) increased the intestinal glycogen concentrations. Similarly, rats treated 
with the standard anti-diabetic drugs, metformin and insulin showed comparable significant 








































Figure 21. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine glycogen concentration with untreated STZ-
diabetic rats and those treated with the standard drugs metformin and insulin. Values are 
presented as means, and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by 











3.8  Hormone concentrations  
In order to determine the effects of OA and MA on insulin and ghrelin secretion, plasma insulin 
and ghrelin concentrations of STZ-induced diabetic rats treated with OA and MA every third day 
for 5 weeks were determined using ELISA. The plasma insulin concentrations of STZ-induced 
diabetic rats which were significantly (p<0.05) low by comparison with those of the non-diabetic 
rats were not altered by any of the treatments (see Figure 22). On the other hand the plasma 
ghrelin concentrations of STZ-induced diabetic rats were significantly (p<0.05) increased by 
comparison with those of the non-diabetic rats after the 5-week experimental period. However, 
treatment of STZ-induced diabetic rats with OA and MA significantly (p<0.05) decreased the 
plasma ghrelin concentrations. Similarly, rats treated with the standard anti-diabetic drugs, 
metformin and insulin showed significant (p<0.05) decreases in plasma ghrelin concentrations 
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Figure 22. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on plasma insulin concentrations with untreated STZ-diabetic rats 
and those treated with the standard drugs metformin and insulin. Values are presented as means, 
and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison to the 






























Figure 23. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on plasma ghrelin concentrations with untreated STZ-diabetic rats 
and those treated with the standard drugs metformin and insulin. Values are presented as means, 
and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison to the 












3.9   Protein expression  
In order to determine the effects of OA and MA on glycogen synthase, SGLT1, GLUT2, α-
glucosidase, α-amylase and ghrelin expression,  Western blot analysis of these proteins was 
conducted in various sections of the gastrointestinal tract in separate groups of non-diabetic, 
untreated STZ-diabetic rats and STZ-diabetic rats treated with OA and MA following the 5 week 
study.  
 
3.9.1  Glycogen synthase   
The expression of glycogen synthase in the small intestine of untreated STZ-induced diabetic 
rats was significantly (p<0.05) decreased by comparison with those of the non-diabetic control 
rats after the 5-week experimental period. Interestingly, treatment of STZ-induced diabetic rats 
with OA and MA significantly (p<0.05) increased the expression of glycogen synthase in the 
small intestine. Similarly, rats treated with the standard anti-diabetic drugs, metformin and 
insulin showed significant (p<0.05) increases in the intestinal expression of glycogen synthase 























































Figure 24. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine glycogen synthase expression with untreated STZ-
diabetic rats and those treated with the standard drugs metformin and insulin. Values are 
presented as means, and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by 






3.9.2  α-amylase and α-glucosidase  
The small intestine α-amylase and α-glucosidase expression of untreated STZ-induced diabetic 
rats were significantly (p<0.05) increased by comparison with those of the non-diabetic control 
rats after the 5-week experimental period. However, treatment of STZ-induced diabetic rats with 
OA and MA significantly (p<0.05) decreased the intestinal expression these carbohydrate 
hydrolyzing enzymes. STZ-diabetic rats treated with standard drugs metformin and insulin 


























































Figure 25. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine α-amylase expression with untreated STZ-diabetic 
rats and those treated with the standard drugs metformin and insulin. Values are presented as 
means, and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison 









































Figure 26. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine α-glucosidase expression with untreated STZ-
diabetic rats and those treated with the standard drugs metformin and insulin. Values are 
presented as means, and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by 







3.9.3   SGLT1 and GLUT2 
The small intestine expression of SGLT1 and GLUT2 in STZ-induced diabetic rats were 
significantly (p<0.05) increased by comparison with those of the non-diabetic rats after the 5-
week experimental period. On the other hand, treatment of STZ-induced diabetic rats with OA 
and MA significantly (p<0.05) decreased the intestinal expressions of SGLT1 and GLUT2. STZ-
diabetic rats treated with standard drugs metformin and insulin showed a similar response pattern 






















































Figure 27. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine SGLT1 expression with untreated STZ-diabetic 
rats and those treated with the standard drugs metformin and insulin. Values are presented as 
means, and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison 









































Figure 28. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine GLUT2 expression with untreated STZ-diabetic 
rats and those treated with the standard drugs metformin and insulin. Values are presented as 
means, and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison 






3.9.4  Ghrelin 
The expression of ghrelin in the gastric fundus, small and large intestine of STZ-induced diabetic 
rats was significantly (p<0.05) increased by comparison with those of the non-diabetic rats after 
the 5-week experimental period. On the other hand, treatment of STZ-induced diabetic rats with 
OA and MA significantly (p<0.05) decreased the expression of ghrelin in the gastric fundus as 
well as in the small and large intestine. Additionally, STZ-diabetic rats treated with standard 
drugs metformin and insulin showed a similar response pattern of results (see Figure 29, Figure 




















































Figure 29. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on gastric fundus ghrelin expression with untreated STZ-diabetic rats 
and those treated with the standard drugs metformin and insulin. Values are presented as means, 
and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison to the 










































Figure 30. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine ghrelin expression with untreated STZ-diabetic 
rats and those treated with the standard drugs metformin and insulin. Values are presented as 
means, and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison 





































Figure 31. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on large intestine ghrelin expression with untreated STZ-diabetic rats 
and those treated with the standard drugs metformin and insulin. Values are presented as means, 
and vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison to the 














3.10   Oxidative stress  
In order to determine the effects of OA and MA on oxidative stress, we measured levels of 
MDA, a commonly known marker of oxidative stress and levels of antioxidant defence enzymes 
SOD and GPx in the small intestines of non-diabetic control, untreated STZ-diabetic and STZ-
diabetic rats treated with OA and MA following the 5 week study. The concentrations of MDA 
and antioxidant enzymes (SOD and GPx) in non-diabetic control rats represent baseline/ normal 
activity levels found in the small intestine. There was a significant (p<0.05) increase in intestinal 
MDA concentrations and a simultaneous significant (p<0.05) decrease of SOD and GPx activity 
in the untreated STZ-diabetic rats by comparison with the non-diabetic control rats. Treatment of 
the STZ-diabetic rats with OA and MA significantly (p<0.05) reduced the MDA concentrations 
while significantly (p<0.05) increasing the activities of SOD and GPx in the small intestine 
thereby reversing the changes seen in the untreated STZ-diabetic rats. Similar effects were 
observed in STZ-diabetic rats treated with the standard drugs metformin and insulin (see Figure 

































Figure 32. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on MDA concentration with untreated STZ-diabetic rats and those 
treated with the standard drugs metformin and insulin. Values are presented as means, and 
vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison to the non-












































Figure 33. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine SOD activity with untreated STZ-diabetic rats and 
those treated with the standard drugs metformin and insulin. Values are presented as means, and 
vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison to the non-








































Figure 34. Comparison of the effects of OA and MA administered in STZ-diabetic rats twice 
every third day for 5 weeks on small intestine GPx activity with untreated STZ-diabetic rats and 
those treated with the standard drugs metformin and insulin. Values are presented as means, and 
vertical bars indicate SEM of means (n = 6 in each group).♦=p<0.05 by comparison to the non-












3.11   Histological studies 
To investigate the effects of OA and MA on the structural integrity of the small intestine, 
haematoxylin and eosin staining was performed in the small intestines of non-diabetic control, 
untreated STZ-diabetic and STZ-diabetic rats treated with OA and MA following the 5 week 
study. H and E-stained sections of untreated STZ-diabetic rats showed disruptions in the 
longitudinal layer of the small intestine by comparison with those of the non-diabetic controls 
observed under a light microscope. On the other hand, the intestinal mucous membrane in the 
circular layer of the small intestines of the untreated STZ-diabetic rats showed observable 
reductions in the length of the villi and disruption in the brush-border membrane by comparison 
with the non-diabetic rats. However, those animals treated with OA and MA showed no 
disruptions in the longitudinal layer by comparison to those of the untreated STZ-diabetic rats. 
Additionally, intact brush-border membranes and increases in the height of the villi were 
observed in those animals treated with OA and MA when compared to the untreated STZ-
diabetic groups. Similar results were observed in animals treated with the standard drugs 







Figure 35. H & E stains illustrating the effects of OA and MA on the morphology of the small 
intestine in STZ-induced diabetic rats. Picture A represents an intact longitudinal layer (blue 
arrow), an intact mucous membrane (yellow arrow), goblet cells in the circular layer (orange 
arrow) and normal length villi (black arrow) in non-diabetic control animals. Picture B represents 
a disrupted longitudinal layer, an intact mucous membrane, goblet cells in the circular layer and 
villi with reduced length in untreated STZ-diabetic control animals. Pictures C, D, E and F 
represent an intact longitudinal layer, an intact mucous membrane, goblet cells in the circular 








CHAPTER 4  
DISCUSSION 
The aim of the present study was to investigate the effects of Syzygium-aromaticum derived 
triterpenes, OA and MA on intestinal glucose handling in STZ-induced diabetic rats in an effort 
to further elucidate the hypoglycaemic mechanisms of the triterpenes. The results suggest that 
Syzygium aromaticum-derived OA and MA prevents of postprandial hyperglycaemia in 
streptozotocin-induced diabetic rats primarily through the modulation of intestinal glucose 
handling. . The findings of the current study are of considerable importance as they not only 
further explain the hypoglycaemic effects of OA and MA but they also justify the use of the 
small intestine as a therapeutic target in the management of diabetes mellitus.  
 
 





C-NMR were comparable to the previously reported data (Mahato and Kundu, 
1994; Mapanga et al., 2009; Uddin et al., 2011). The presence of the olefenic bond between C-
12 and C-13 bond served as confirmation that the two compounds were indeed triterpenes as this 
is a bond unique to triterpenes (García-Granados et al., 2000; Ju´lio et al., 2003).  Additionally, 
the identification of MA was confirmed through the C-2 which represents a hydroxyl group that 
is absent in other triterpenes like oleanolic acid (OA) and ursolic acid (UA) (Ju´lio et al., 2003).   
The induction of experimental diabetes using streptozotocin significantly increased plasma 
ghrelin concentrations in male Sprague-Dawley rats. Ghrelin acts on peripheral and central 
targets to stimulate food intake (Nakazato et al., 2001; Wren et al., 2001). Plasma levels of this 
peptide increase on fasting and decrease after habitual feeding, thus showing a pattern reciprocal 
to that of insulin (Broglio et al., 2001; Egido et al., 2002; Reimer et al., 2003; Dezaki et al., 
2004). Enhanced plasma ghrelin levels have been observed in diabetic patients are associated 
with diabetic polyphagia (Ariyasu et al., 2001). This increase in food consumption causes the 
body to spend more time in the postprandial state leading to chronic hyperglycaemia (Ariyasu et 
al., 2001; Broglio et al., 2001; Delhanty and van der Lely, 2011). This study served to advance 
the current knowledge on how OA and MA achieve and maintain glucose homeostasis in 
experimental type 1 diabetes mellitus in Sprague-Dawley rats.  
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In order to ensure that there was no residual insulin secretion in the rats, pancreatic β-cells were 
obliterated using a single intraperitoneal injection of STZ (60 mg/kg in citrate buffer, pH 6.3). 
STZ is an antibiotic first isolated from Streptomyces achromogenes selectively destroys 
pancreatic β-cells by inducing cytotoxicity effects in these cells (Weiss, 1982; Pinent et al., 
2004). The glucose moiety of STZ is important for recognition by the β-cells and thus selectively 
facilitates the entry of STZ into these cells through the GLUT2 transporter (Coskun et al., 2005). 
Studies show that STZ to induces cytotoxicity of the pancreatic B-cells through the alkylation of 
DNA as well as through the generation of reactive oxygen species. Furthermore, STZ has been 
reported to inhibit the Krebs cycle to decrease oxygen consumption which leads to the reduction 
of ATP levels. Finally, the pro-apoptotic genes are expressed thus causing β-cell death 
(Sztudelski, 2001). Additionally, previous studies have shown that the toxic effects of 
streptozotocin are short-lived and that this compound is quickly removed from circulation 
therefore suggesting that the observed effects in the animals are due to derangements in insulin 
secretion (Papaccio et al., 1991; Kwon et al., 1994; Sztudelski, 2001; Bhor et al., 2004). 
Indeed, the plasma insulin concentrations were significantly lower in the untreated STZ-induced 
diabetic rats by comparison with the non-diabetic rats. Furthermore, there were increases in 
plasma ghrelin levels that were possibly a result of the increased gastrointestinal expression of 
this hormone. This was further accompanied by significant increases in food intake as well as 
fasting and postprandial blood glucose concentrations in the untreated STZ-induced diabetic rats 
by comparison with the non-diabetic control rats. Taking this information into consideration, we 
were able to investigate the effects of OA and MA intestinal glucose handling without the 
influence of pancreatic insulin secretion thus mimicking an experimental type 1 diabetes model.  
However, administration of OA and MA significantly reduced the food intake in the STZ-
diabetic rats. This was possibly due to reduced plasma ghrelin levels that were associated with 
reduced gastrointestinal expression of this hormone after treatment with OA and MA. This 
reduction in food intake possibly decreased the amount of glucose available for absorption into 
circulation.  Furthermore, the administration of these triterpenes to STZ-diabetic rats 
significantly reduced the blood glucose concentrations in both the acute and sub-chronic studies. 
These results are in agreement with previous observations from studies conducted in our 
laboratory (Mapanga et al., 2009; Musabayane et al., 2010; Ngubane et al., 2011; Mkhwanazi et 
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al., 2014). Interestingly, both OA and MA had no significant effect on plasma insulin 
concentrations in the STZ-diabetic rats suggesting that the blood glucose lowering effects may 
be exerted via extra-pancreatic mechanisms. In addition, previous studies have indeed shown that 
while triterpenes such as OA enhance insulin secretion in isolated pancreatic islets, they have no 
effects on plasma insulin concentrations in whole animal studies (Teodoro et al., 2008; 
Musabayane et al., 2010) Indeed, OA and MA administration did not have significant effects on 
blood glucose concentrations in non-diabetic rats following a carbohydrate challenge. This could 
perhaps be due to the masking effects of insulin arising from the functional β-cells.  
Plant bioactive compounds such as triterpenes have been reported to exert their anti-
hypoglycaemic effects through a variety of mechanisms (Grover et al., 2002; Ali et al., 2002 ; 
Dzubak et al., 2006 ; Bhat et al., 2008; Abdul-Ghani and Defronzo, 2014). One of these 
mechanisms is slowing down the absorption of glucose in the small intestine to prevent 
postprandial hyperglycaemia (Ferraris, 2001; Kim et al., 2008). This can be mediated through 
the modulation of key carbohydrate hydrolyzing enzymes such as α-amylase and α-glucosidase 
as well as intestinal glucose transporters such as SGLT1 and GLUT2 (Floris et al., 2005; Jong-
Anurakkhun et al., 2007; Bhandari et al., 2008). Enzyme inhibitor drugs such as acarbose, 
miglitol and voglibose prevent postprandial hyperglycaemia through the inhibition of the 
carbohydrate hydrolyzing enzymes to delay digestion and absorption of dietary carbohydrates 
(Dhindsa et al., 2002). These drugs are characterized by their potency and mode of inhibition. 
The potency of an enzyme inhibitor is usually determined and reported in terms of an IC50 value 
which is the concentration of the inhibitor corresponding to 50% inhibition (DeFronzo et al., 
2014). In the current study, the potency of OA and MA as inhibitors of sucrase, and α-
glucosidase and α-amylase were assessed and reported in terms of IC50 values. Interestingly, the 
in vitro studies indicated that the IC50 values of OA and MA against sucrase, α-amylase and α-
glucosidase at various concentrations were less than those shown of acarbose suggesting that 
these triterpenes are highly potent and have fewer side effects.  
Acarbose is associated with gastrointestinal side effects due to excessive inhibition of pancreatic 
α-amylase, resulting in the abnormal bacterial fermentation of undigested carbohydrates in the 
large intestine (Hanefeld, 1998; Kwon et al., 2007b).  Furthermore, acarbose has been reported 
to increase the incidence of renal tumors, serious hepatic injury, and acute hepatitis (Diaz-
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Gutierrez et al., 1998; Charpentier et al., 2000). Against this background are reports that several 
α-glucosidase inhibitors isolated from medicinal plants possess lesser adverse effects than the 
existing drugs (Matsuda et al., 2002; Gowri et al., 2007; Tarling et al., 2008; Kim et al., 2009). 
Indeed, the in vivo results also suggest that OA and MA inhibit the activity of key carbohydrate 
hydrolyzing enzymes. This was shown through the suppression of postprandial hyperglycaemia 
and significant reductions in AUCglucose in the OGT studies. This was further evidenced through 
the down-regulation in the intestinal expression of both α-amylase and α-glucosidase following 
the sub-chronic study. The down-regulation of these enzymes in the small intestines by the OA 
and MA, in a manner similar to the standard drug metformin possibly contributed to the 
prevention of postprandial hyperglycaemia (Brayer et al., 2000; Raptis and Dimitriadis, 2001). 
Metformin is an anti-diabetic drug that was first isolated from the plant Galega officinalis. This 
drug prevents postprandial hyperglycaemia, in part, through the inhibition of gastric emptying 
and intestinal glucose transport (Dhindsa et al., 2002; Musi et al., 2002; Mahomoodally et al., 
2006; Mahrouf et al., 2006). Phlorizin is another plant-derived (Malus domestica) drug that is 
used to prevent postprandial hyperglycaemia (Eddouks and Maghrani, 2004; Ehrenkranz et al., 
2005). The structure of phlorizin consists of a glucose moiety and two aromatic rings joined by 
an alkyl spacer thus allowing this drug to be a specific and competitive inhibitor of the SGLT 
transporters located within the small intestine (Panayotova-Heiermann et al., 1995). Glucose is 
actively taken up from the lumen of the small intestine into the cells across the brush-border 
membrane by a Na
+
-dependent glucose co-transporter (SGLT1) and then exits the cell across the 
basolateral membrane by a Na
+
-independent glucose transporter (GLUT2) (Mizuma, 1993; 
Hediger and Rhoads, 1994; Strugala et al., 1995; Meinild et al., 1998). The inhibition of 
intestinal glucose transporters has been considered as a potential target for drug development for 
glycaemic control in diabetes mellitus (Coady et al., 1990; Lee et al., 1994; Asano et al., 2004).  
 
This study accordingly also investigated the influence of OA and MA on glucose transport across 
the small intestine using the rat everted gut sacs in vitro. The everted gut sac technique 
developed by Wilson and Wiseman, (1954) is a standard method for studying the absorption of 
substances in the mammalian intestine in vitro (Wilson and Wiseman, 1954; Porteous et al., 
1984; Burgmann et al., 1992; Tandon et al., 1993; Obatomi et al., 1994; Mahomoodally et al., 
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2005; Mahomoodally et al., 2006). The results show that both OA and MA inhibited glucose 
absorption in the small intestine. OA and MA, like phlorizin, significantly inhibited the intestinal 
mucosal glucose absorption and simultaneously inhibited glucose release into serosal fluid.  
Indeed, the administration of OA and MA in STZ-diabetic glucose-loaded rats significantly 
reduced postprandial glucose concentrations. Furthermore, Western blot analysis showed that 
untreated STZ-induced diabetic rats exhibited increased SGLT1 and GLUT2 expression in the 
small intestine over the 5-week study in comparison to non-diabetic control animals. Studies 
have shown in rats with experimentally induced diabetes that the capacity of the small intestine 
to absorb glucose increases at least in part, due to enhanced activity and abundance of brush 
border SGLT1 and basolateral GLUT2 (Dyer et al., 1997a; Dyer et al., 1997b; Liu et al., 2012; 
Tahrani et al., 2013). However, the results also indicate that administration of OA and MA 
significantly reduced the expression of these transporters in STZ-diabetic rats suggesting that the 
blood glucose lowering effects of these triterpenes could arise, in part through the inhibition of 
intestinal glucose transporters. The down regulation of these transporters by OA and MA reduces 
the total glucose absorption capacity in the small intestine in diabetes and therefore significantly 
reduces the magnitude of postprandial hyperglycaemia.  
 
Other studies have noted that when intestinal glucose inhibitors such as phlorizin are taken for 
extended periods, they lead to adverse side-effects such as polyuria, glycosuria and extreme 
weight loss (Charpentier et al., 2000; Beckman et al., 2002; Kwon et al., 2007b; Tahrani et al., 
2013). These are classical symptoms of diabetes mellitus and thus, the administration of these 
drugs may worsen the diabetic condition. Indeed, the results of the present study revealed that 
there was marked reduction in the total body weights of the untreated STZ-diabetic group 
compared to that of the non-diabetic control group. On the contrary, treatment with OA and MA 
stabilized the body weights of the STZ-induced diabetic rats suggesting that there may be a 
compensatory mechanism. Additionally, we have previously shown that OA and MA reduce 
blood glucose concentrations of STZ-induced diabetic rats through a variety of mechanisms 




We suggest that OA and MA, apart from inhibiting glucose transport from the mucosa to the 
serosa, these triterpenes could possibly shunt the glucose accumulated within the gut wall 
towards glycogen synthesis. This is consistent with our observations of increased glycogen 
concentrations in the small intestine as well increased expression of the glycogenic enzyme 
glycogen synthase. In keeping with this hypothesis, there are several reports of the presence of 
glycogen stores and insulin sensitive enzymes, glucose-6-phosphatase (Glc6Pase), glycogen 
phosphorylase and glycogen synthase in both rodent and human small intestines (Anderson and 
Jones, 1974 ; Rousset et al., 1984 ; Croset et al., 2001). We have previously reported that the 
hypoglycaemic effects of OA and MA are exerted in part via increased glycogen synthesis in the 
liver and skeletal muscle (Ngubane et al., 2011; Mkhwanazi et al., 2014). In addition, MA has 
been reported to reduce hepatic glucose production at least in part, through inhibiting glycogen 
phosphorylase activity (Singh et al., 1992). Inhibition or inactivation of glycogen phosphorylase 
has been regarded as the remedial strategy for the control of blood glucose in diabetes (Chen et 
al., 2006). Glycogen inhibition activates glycogen synthase, a critical component of the 
mechanism of glycogen synthesis (Aiston et al., 2003). Indeed, the current study suggests that 
the observed increases in intestinal glycogen concentration of STZ-diabetic rats treated with OA 
and MA could be mediated through an increase in the expression of glycogen synthase as 
determined through Western blot analysis.  
 
This conversion of glucose to glycogen in the small intestine reduces the amount of glucose 
available for the generation of reactive oxygen species.  The continued generation of reactive 
oxygen species has been shown to contribute to the progression of diabetic complications, 
consequently, there are various drugs used to inhibit the generation of reactive oxygen species 
(Pazdro and Burgess, 2010). Indeed, OA and MA have been shown in the current study to 
suppress reactive oxygen species formation as seen through significant reductions in MDA levels 
which is a marker of lipid peroxidation. These triterpenes have also been shown to increase the 
activity of antioxidant defence enzymes such as glutathione peroxidase and superoxide 
dismutase (Mkhwanazi et al., 2014). Current anti-diabetic drugs such as captopril, allopurinol, 
melatonin and metformin are used to suppress the elevation of reactive oxygen species in 
diabetes mellitus (Dhindsa et al., 2002; Musi et al., 2002; Mahrouf et al., 2006).  Captopril has 
been reported to increase  superoxide dismutase levels and  decrease  MDA concentration in the 
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plasma (Shirpoor et al., 2009). Allopurinol inhibits xanthine oxidase which is involved in the 
production of hydrogen peroxide and superoxide. Metformin is also used in the management of 
reactive oxygen species in diabetes mellitus. The antioxidant effects of metformin are exerted 
through the inhibition of NADPH oxidase which contributes to the generation of reactive oxygen 
species particularly in the kidneys and small intestines. Metformin also lowers the mitochondrial 
respiration chain thus reducing the formation of superoxide iron (Mahrouf et al., 2006).  This 
drug therefore inhibits lipid peroxidation and elevates glutathione levels (Gumieniczek, 2005). 
The elevation of reactive oxygen species results in structural changes in the small intestine that 
further lead to the development of diabetic complications. Indeed, haematoxylin and eosin 
staining showed that the intestinal mucous membrane of the STZ-diabetic rats showed significant 
reductions in the length of the villi by comparison with the non-diabetic rats. These results can 
be related the functional activity of L-glutamine which is considered the main energy source for 
the enterocytes to promote proliferation and cellular migration of the intestinal mucosa (Bhor et 
al., 2004; Katz et al., 2007). L-glutamine is a precursor of glutathione which is significantly 
reduced in diabetes mellitus (Bhor et al., 2004; Coskun et al., 2005; Gao et al., 2009; Kim et al., 
2009). However, those animals treated with OA and MA had significant increases in the height 
of the villi when compared to the untreated STZ-diabetic groups. Indeed, this could be related to 
the significant increases in superoxide dismutase and glutathione peroxidase activity in the small 
intestine. Indeed, several studies have shown that various medicinal plant extracts such as those 
of Allium sativum, Emblica officinalis and Momordica charantia possess beneficial effects on 
the oxidative status of rats with experimental diabetes (Khanna et al., 1981; Bhor et al., 2004; 
Coskun et al., 2005; Uebanso et al., 2007). These effects have been observed with simultaneous 
improvements in postprandial blood glucose concentrations. OA and MA have also been shown 
to possess antioxidant properties in experimental diabetes that arise through the alleviation of 
reactive oxygen species due to reduced blood glucose levels.  
 
This study identifies the small intestine as a glycogen synthesizing organ which may be involved 
in the pathophysiology of diabetes. OA and MA have been found to possibly play a role in the 
reduction in gastrointestinal expression of ghrelin leading to reduced food intake. Western blot 
analysis not only confirmed the inhibitory effects of OA and MA against α-glucosidase and 
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pancreatic α-amylase, but additionally showed that the triterpenes decrease the levels of SGLT 
and GLUT2 in the small intestines of STZ-induced diabetic rats to perhaps reduce glucose 
reabsorption (Hediger and Rhoads, 1994; Meinild et al., 1998). The results, therefore, extend our 
in vitro observations by showing that the hypoglycaemic effects of OA and MA are in part 
mediated via inhibition of carbohydrate hydrolyzing enzymes as in the small intestines of 
diabetic rats. Taken together, the in vitro and in vivo observations of the study suggest that the 
control of the intestinal absorption of glucose by OA and MA may constitute an avenue of 
glycaemic control in diabetes. Additionally, the data suggests that OA and MA could be used as 
a potential supplements for treating postprandial hyperglycemia. We believe that these results 
will certainly enable a better understanding of the mechanisms involved in the pathophysiology 
of human diabetes and further justify the use of the small intestine as a target in the management 

















5.0  Conclusions  
The results presented in the current study show that S. aromaticum-derived OA and MA exert 
their blood glucose lowering effects in part, through the reduction of food intake mediated 
through a decrease in the gastrointestinal expression of ghrelin. Furthermore, this study shows 
that the hypoglycaemic effects of OA and MA could be due to increased glycogen synthesis in 
the small intestine. The results also show that OA and MA prevent postprandial hyperglycaemia 
in STZ-induced diabetic rats. This is mediated in part, through reductions in the intestinal 
expression of carbohydrate hydrolyzing enzymes such as α-amylase and α-glucosidase as well 
intestinal glucose transporters such as SGLT1 and GLUT2.  
Additionally, OA and MA alleviate oxidative stress in the small intestine of STZ-diabetic rats. 
Taken together, the results suggest that OA and MA modulate intestinal glucose homeostasis in 
diabetes mellitus through the prevention of postprandial hyperglycaemia and can therefore 
prevent the development of diabetic complications. The results of this study are of considerable 
importance as they add further knowledge in the bid to fully elucidate the mechanism of the 
hypoglycaemic effects of these triterpenes and further explain the role of the gastrointestinal tract 
in the management of diabetes mellitus. 
  
5.1 Limitations and directions for future studies  
One of the limitations of the current study is that plasma leptin levels were not measured after 
the 5-week study. This hormone plays a role in the regulation of the hunger-satiety cycle. 
Another limitation of the study is that the effects of OA and MA on the enzyme glucose-6-
phosphatase were not determined. This is a gluconeogenic enzyme that has been implicated to 
play a role in intestinal glucose homeostasis. Due to time constraints, we were not able to 
determine the effects of OA and MA on other glycogenic enzymes. This study therefore also 
opens up further investigations on the effects of these triterpenes on the expression of other 
glycogenic enzymes such as hexokinase and glucokinase. Additionally, the effects of OA and 
MA on the measured parameters were investigated in isolation. In order to further elucidate the 
anti-diabetic mechanisms of these triterpenes, they should be investigated in combination with 
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standard anti-diabetic drugs. Further studies should also look at the expression of the various 
transporters, enzymes and hormones at the gene level using techniques such as polymerase chain 
reaction (PCR) and microarrays to fully establish the mechanisms used by OA and MA to exert 
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Available evidence suggests that Syzygium spp ethyl acetate solubles (EAS) contain triterpene 
mixtures (oleanolic/ursolic acid and methyl maslinate/methyl corosolate) with hypoglycaemic 
properties in streptozotocin (STZ)-induced diabetic rats. Accordingly, maslinic acid (MA) was 
isolated from S. aromaticum. Air-dried powdered flower buds of S. aromaticum were sequentially 
extracted thrice at 24 h intervals with 3 litres on each occasion of hexane, dichloromethane, ethyl 
acetate and methanol. The stereostructure of MA obtained following recrystallization with 
chloroform and methanol was elucidated by 1 h- and 13C-NMR spectroscopy (1D and 2D) on 
chemical and physicochemical evidence. Oral glucose tolerance (OGT) responses to various doses of 
MA (20, 40 and 80 mg.kg-1, p.o.) were monitored in non-diabetic and STZ-induced diabetic rats 
after an 18-h fast. Rats treated with deionized water or metformin acted as untreated and treated 
positive controls, respectively. Blood glucose concentrations were measured at 15-min intervals for 
the first hour, and hourly thereafter for 3 h. Short-term effects were monitored after 6 h in animals 
treated with MA twice daily by means of a bulbed steel tube for a period of 5 weeks while, food and 
water intake as well as body weight were monitored 24 hours after treatment every third day. All 
results are presented as mean± standard error means where P<0.05 denotes statistical significance. 
All doses of MA significantly decreased blood glucose of non-diabetic and STZ-induced diabetic rats 
throughout the experimental period. Comparisons of the blood glucose lowering effects of the MA 
doses at each time appeared to be dose-dependent in STZ-induced diabetic rats. MA administration 
reduced the body weight loss of STZ-induced diabetic rats without altering food intake. The results 
suggest that MA, like metformin, contains blood glucose lowering properties suggesting that it is a 
potential drug for the management of type 1 diabetes mellitus.  
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Enhanced plasma ghrelin levels have been observed in rats with streptozotocin-induced diabetes and are 
associated with diabetic polyphagia. This increase in food consumption causes the body to spend more 
time in the postprandial state and in diabetes mellitus this could lead could lead chronic hyperglycaemia. 
Consequently, this contributes to the development of micro- and macrovascular complications of diabetes. 
The subcutaneous administration of insulin has been shown to reduce plasma ghrelin concentrations; 
however, this has been associated with the development of hyperinsulinaemia. Recent reports from our 
laboratory indicate that Syzygium aromaticum derived oleanolic acid (OA) and maslinic acid (MA) reduce 
postprandial hyperglycaemia, in part, through the inhibition of intestinal carbohydrate hydrolyzing 
enzymes, however, their effects on the gastrointestinal expression of ghrelin are not yet known. 
Accordingly, this study investigated the effects of these triterpenes on gastrointestinal ghrelin expression 
in streptozotocin induced diabetic rats. The effects of OA and MA on blood glucose concentration, food 
and water intake as well as body weight changes were evaluated in STZ-induced diabetic rats kept on a 
standard rat diet for 5-weeks. Plasma ghrelin and insulin concentrations were investigated after the study. 
Furthermore the expression of ghrelin was analyzed by Western blot analysis in the gastrointestinal tract. 
The induction of diabetes significantly increased plasma ghrelin concentrations in comparison to the non-
diabetic control. Interestingly, the administration of the triterpenes, like insulin, reduced food intake, 
blood glucose levels and plasma ghrelin levels in STZ-induced diabetic rats. This was accompanied by 
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The hypoglycaemic effects of Syzygium aromaticum derived triterpene, oleanolic acid (OA) in 
streptozotocin (STZ)-induced diabetic rats are mediated in part via increased hepatic glycogen 
synthesis [1]. The wide range of available anti-diabetic suggests that a variety of mechanisms of 
action are involved in the blood glucose lowering effects. The present study was designed to 
investigate the effects of OA on glucose transport in vitro using the everted rat intestinal protocol 
which has been previously described by Mahomoodally et al., 2005. [2] Everted intestinal sacs 
from rats filled with 1 ml of Krebs-Henseleit bicarbonate buffer (KHB) were mounted in an 
organ bath containing 50 ml of the same incubation medium. D-glucose (10 mM) was added to 
the medium just before the start of the appropriate experiments. In separate preparations graded 




 M) were 
incubated for 30 min in in the mucosal bathing fluid containing glucose (10 mM) to investigate 
effects on glucose transport across the intestine gut wall. The external incubation medium will be 
continuously bubbled with gas mixture of 95% oxygen) and 5% carbon dioxide during the whole 
incubation period. The organ bath was surrounded by a water jacket maintained at 37-40 °C. The 
transport of D-glucose was evaluated by measuring the increase in glucose concentration inside 
the intestinal sacs after 30 min of incubation. The change in glycogen concentration in the gut 
wall was interpreted as assessed glucose metabolized. Graph Pad Instat software (version 4) 
using one way analysis of variance (ANOVA) followed by Tukey- Kramer multiple comparison 
test was used. P values < 0.05 were considered significant. Lower concentration (0.375 and 
0.750 mM) of OA significantly inhibited (p < 0.05) D-glucose transport across the rat everted 
intestinal sac in a dose-dependent manner whereas the inhibitory effects of higher concentrations 
of 0.750, 1.500 and 3.000 mM could not be statistically separated. Phlorizin, however, exhibited 
dose-dependent inhibition of glucose uptake across the everted intestinal sac. The accumulation 
of glycogen concentration in the gut wall increased significantly in the presence of OA. The fate 
of glucose retained within intestinal wall is difficult to quantify since glucose is rapidly 
metabolized by enterocytes. We hypothesize that OA inhibits the active transport of d-glucose 
suggesting that the triterpene can be a potential alternative drug therapy of postprandial 
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Recent studies in our laboratory suggest that the hypoglycaemic effects of plant-derived 
triterpenes oleanolic acid (OA) and maslinic acid (MA) arise, in part, through the reduction of 
food intake. Conventional treatments reduce food intake through the suppression of ghrelin 
secretion and therefore prevent sustained hyperglycaemia.  
Accordingly, we investigated the effects of OA and MA on plasma ghrelin concentrations as 
well as gastrointestinal ghrelin expression in non-diabetic and STZ-induced diabetic rats treated 
with OA and MA for 5 weeks. We determined the plasma ghrelin concentrations of non-diabetic 
and STZ-induced diabetic rats treated with OA and MA for 5 weeks using ELISA. The results 
have shown that the plasma ghrelin concentrations of untreated diabetic rats were significantly 
increased compared to non-diabetic rats (3.42±0.17 vs. 1.99±0.06 mmol/L) respectively. 
Interestingly, the plasma ghrelin concentrations of triterpene-treated diabetic rats were 
significantly decreased to levels comparable with the non-diabetic control (OA: 1.96±0.17; MA: 
2.43±0.11 mmol/L).  
Furthermore, we also determined the ghrelin gene expression in the gastrointestinal tract using 
Western blot analysis.  The results show that the ghrelin expression of untreated diabetic rats was 
greatly increased in comparison to the non-diabetic rats. However, the gastric and intestinal 
expressions of triterpene-treated rats were significantly reduced in comparison to the STZ-
diabetic control.  
We conclude that the anti-hyperglycaemic properties of OA and MA arise, in part, through the 
reduction of food intake mediated by decreases in plasma ghrelin concentrations. Therefore, OA 
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ABSTRACT  
Dietary carbohydrate hydrolysis in the small intestine increases the magnitude and duration of 
postprandial hyperglycaemia in diabetes leading to the development of macro- and 
microvascular complications. Indeed, drugs such as acarbose and miglitol which inhibit key 
carbohydrate hydrolyzing enzymes in the small intestine are used to manage diabetes.  Reports 
indicate that Syzygium spp-derived oleanolic acid (OA) and maslinic acid (MA) possess 
hypoglycaemic properties, but their effects on postprandial hyperglycaemia and intestinal 
carbohydrate metabolism remain unclear. Accordingly, this study was designed to investigate the 
effects of OA and MA on intestinal carbohydrate hydrolyzing enzymes and postprandial blood 
glucose concentrations in non-diabetic and STZ-induced diabetic rats associated with 
polysaccharide, disaccharide and monosaccharide challenge after an 18h fast. To assess the 
influence of OA and MA on intestinal glucose transport, the expression of SGLT1 and GLUT2 
were assessed in small intestines isolated from rats treated with OA and MA twice daily for 5 
weeks using Western blot analysis.  
OA and MA ameliorated postprandial hyperglycemia in carbohydrate loaded diabetic rats as 
indicated by the significantly small glucose area under the curve (AUC0-2h) in treated diabetic 
animals compared with untreated diabetic rats. Western blotting showed significantly elevated 
SGLT1 and GLUT2 expressions in the small intestine tissues of untreated STZ-induced diabetic 
rats compared with control non-diabetic animals. OA and MA treatment not only down-regulated 
the diabetes-induced increase of these transporters, but also inhibited intestinal α-amylase and α-
glucosidase activity. These results suggest that OA and MA could be used as potential 
supplements for treating postprandial hyperglycaemia. 
 
Keywords : Postprandial glucose; α-glucosidase; α-amylase;  





PSSA 2011, Wyndham entry 8 
Effects of Syzygium aromaticum-derived oleanolic acid on glucose transport and glycogen 










Faculty of Health Sciences, Discipline of Human Physiology Faculty of Science and 
Agriculture, 
2




In the present study, we investigated the effects of oleanolic acid (OA), which has hypoglycemic 
properties, on glucose transport and glycogen synthesis in the small intestine, an organ that 
secretes enzymes involved in carbohydrate metabolism. The OA was isolated from Syzygium 
aromaticum ethyl acetate-soluble fractions followed by recrystallization with ethanol. It was 
diluted to required concentrations in freshly prepared dimethyl sulphoxide (2 mL) and normal 
saline (19 mL) before being administered to rats (p.o.). Glycogen concentrations were 
determined in isolated small intestines from fasted and non-fasted non-diabetic and 
streptozotocin-diabetic rats after 18 h treatment with 80 mg/kg, p.o., OA or standard 
hypoglycemic drugs (i.e. 100 μg/kg, s.c., insulin; 500 mg/kg, p.o., metformin). In a separate 
series of experiments, the effects of 30-min incubation with graded concentrations of OA (0.82-
6.56 mmol/L) on d-glucose were evaluated by monitoring changes in glucose concentrations 
inside and outside of intestinal sacs isolated from fasted, non-diabetic rats and mounted in an 
organ bath containing Krebs-Henseleit bicarbonate buffer. All in vivo treatments increased the 
glycogen concentration in rat small intestine, although the effects of metformin treatment in non-





 mol/L) decreased glucose transport from the mucosa to the serosa. The 
data suggest that OA may be a potential alternative drug treatment for postprandial 
hyperglycemia because of its inhibition of glucose uptake across the small intestine and its 
concomitant conversion of glucose to glycogen in the intestinal wall. 
